MeSH term
Frequency | Condition_Probility | Female | 1711 | 2.0 |
Humans | 2306 | 1.0 |
Meta-Analysis | 2 | 1.0 |
Pregnancy | 309 | 5.0 |
Pregnancy Outcome | 5 | 1.0 |
Pregnancy Rate | 2 | 1.0 |
Pregnancy, Multiple | 2 | 1.0 |
Randomized Controlled Trials | 2 | 0.0 |
Adolescent | 438 | 2.0 |
C-Reactive Protein/analysis | 3 | 0.0 |
Calcitonin/blood | 2 | 6.0 |
Child | 106 | 0.0 |
Child, Preschool | 43 | 0.0 |
Comparative Study | 293 | 1.0 |
English Abstract | 190 | 1.0 |
Infant | 23 | 0.0 |
Male | 1243 | 1.0 |
Prognosis | 24 | 0.0 |
Risk Factors | 10 | 0.0 |
Sensitivity and Specificity | 8 | 0.0 |
Treatment Outcome | 39 | 1.0 |
Adult | 1533 | 2.0 |
Case-Control Studies | 24 | 0.0 |
Prolactin/*blood | 643 | 92.0 |
Steroids | 2 | 8.0 |
Hyperprolactinemia/*etiology/physiopathology | 2 | 100.0 |
Middle Aged | 784 | 1.0 |
Pituitary Gland, Anterior/secretion | 6 | 60.0 |
Prolactin/*blood/secretion | 59 | 98.0 |
Research Support, Non-U.S. Gov't | 846 | 0.0 |
Secretory Rate | 5 | 16.0 |
Time Factors | 199 | 1.0 |
Animals | 338 | 0.0 |
Gene Expression | 17 | 0.0 |
Mice | 62 | 0.0 |
Mice, Inbred C57BL | 6 | 0.0 |
Mice, Inbred DBA | 2 | 0.0 |
Mice, Transgenic | 17 | 0.0 |
Prolactin/*genetics | 16 | 55.0 |
Rats | 170 | 1.0 |
Transcription, Genetic | 15 | 0.0 |
Biological Markers/analysis | 2 | 0.0 |
Prolactin/*blood/immunology | 6 | 100.0 |
Radioimmunoassay | 155 | 8.0 |
Active Transport, Cell Nucleus | 2 | 0.0 |
Caseins/*genetics | 2 | 28.0 |
Cells, Cultured | 76 | 0.0 |
DNA-Binding Proteins/*metabolism | 11 | 0.0 |
*Milk Proteins | 19 | 4.0 |
Phosphorylation | 15 | 0.0 |
Prolactin/*pharmacology | 50 | 61.0 |
*Promoter Regions (Genetics) | 4 | 0.0 |
Trans-Activators/*metabolism | 8 | 0.0 |
Tyrosine/metabolism | 6 | 0.0 |
src Homology Domains | 3 | 0.0 |
Administration, Cutaneous | 2 | 2.0 |
Dose-Response Relationship, Drug | 116 | 1.0 |
Human Growth Hormone/blood | 18 | 31.0 |
Insulin-Like Growth Factor I/metabolism | 13 | 6.0 |
Pituitary Hormones/*blood | 12 | 75.0 |
Pituitary-Adrenal System/physiopathology | 4 | 16.0 |
Prolactin/blood | 402 | 71.0 |
Testis/physiopathology | 3 | 37.0 |
Thyroid Gland/physiopathology | 4 | 21.0 |
Birth Weight | 5 | 3.0 |
Infant, Newborn | 33 | 0.0 |
Postpartum Period | 25 | 31.0 |
Spectrophotometry, Atomic | 2 | 4.0 |
Autoimmunity | 4 | 3.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
Phosphoproteins/genetics | 3 | 2.0 |
Prolactin/pharmacology/*physiology | 4 | 80.0 |
Receptors, Prolactin/physiology | 6 | 66.0 |
Research Support, U.S. Gov't, P.H.S. | 396 | 0.0 |
Signal Transduction | 16 | 0.0 |
Trans-Activators/physiology | 2 | 1.0 |
Age Factors | 31 | 1.0 |
Bromocriptine/therapeutic use | 64 | 87.0 |
Hormone Antagonists/therapeutic use | 6 | 42.0 |
Magnetic Resonance Imaging | 59 | 5.0 |
Prolactin/*blood/drug effects | 3 | 75.0 |
Retrospective Studies | 31 | 0.0 |
Sex Factors | 35 | 2.0 |
Corticotropin/biosynthesis | 3 | 75.0 |
Immunohistochemistry | 76 | 0.0 |
In Situ Hybridization | 16 | 0.0 |
Chi-Square Distribution | 2 | 0.0 |
Follow-Up Studies | 51 | 1.0 |
Growth Hormone/blood | 124 | 51.0 |
Protirelin/*blood | 4 | 66.0 |
Remission Induction | 2 | 0.0 |
Schizophrenia/*blood | 5 | 55.0 |
Statistics, Nonparametric | 7 | 0.0 |
Thyrotropin/blood | 142 | 35.0 |
Triiodothyronine/blood | 42 | 19.0 |
Protein Isoforms/genetics/metabolism | 2 | 1.0 |
Transforming Growth Factor beta/pharmacology | 4 | 1.0 |
Culture Techniques | 18 | 4.0 |
Endometrium/cytology/*metabolism | 4 | 13.0 |
Phosphorylation/drug effects | 4 | 0.0 |
Receptors, Prolactin/metabolism | 8 | 50.0 |
Tissue Distribution | 6 | 0.0 |
Ovary/drug effects/physiology | 2 | 33.0 |
*Estrogen Replacement Therapy | 5 | 4.0 |
Interleukin-6/*blood | 3 | 1.0 |
Lymphocyte Activation | 2 | 0.0 |
*Menopause | 14 | 25.0 |
T-Lymphocytes/*immunology | 2 | 0.0 |
Aged | 295 | 0.0 |
Biological Markers/blood | 13 | 0.0 |
Blood Sedimentation | 3 | 1.0 |
Interleukin-6/blood | 2 | 0.0 |
Receptors, Interleukin-2/blood | 2 | 2.0 |
Severity of Illness Index | 16 | 1.0 |
Sialoglycoproteins/blood | 2 | 6.0 |
Chronic Disease | 16 | 0.0 |
Risperidone/adverse effects/*therapeutic use | 2 | 100.0 |
Schizophrenia/blood/*drug therapy | 11 | 61.0 |
*Schizophrenic Psychology | 8 | 12.0 |
Estradiol/pharmacology | 22 | 8.0 |
Pregnancy/*physiology | 2 | 4.0 |
Pregnancy Trimester, First | 13 | 4.0 |
Prolactin/*secretion | 171 | 88.0 |
Endometrium/*metabolism | 5 | 5.0 |
Menstrual Cycle | 22 | 20.0 |
Receptors, Prolactin/*metabolism | 13 | 52.0 |
Reverse Transcriptase Polymerase Chain Reaction | 19 | 0.0 |
Breast Diseases/*physiopathology | 2 | 100.0 |
Dopamine/*physiology | 28 | 30.0 |
Estradiol/blood | 150 | 27.0 |
Hypothalamus/*physiopathology | 5 | 29.0 |
Kinetics | 127 | 1.0 |
Metoclopramide/diagnostic use | 28 | 96.0 |
*Parity | 2 | 22.0 |
Progesterone/blood | 94 | 37.0 |
Biological Markers | 2 | 0.0 |
Embryo Transfer | 5 | 6.0 |
Forecasting | 2 | 0.0 |
Human Growth Hormone/metabolism | 2 | 10.0 |
Luteinizing Hormone/metabolism | 7 | 25.0 |
Pituitary Hormones/metabolism | 3 | 37.0 |
Dopamine Antagonists/*therapeutic use | 3 | 75.0 |
Human Growth Hormone/*secretion | 6 | 15.0 |
Infertility, Female/*etiology/metabolism | 2 | 100.0 |
Metoclopramide/*therapeutic use | 5 | 62.0 |
Receptors, Dopamine D2/*antagonists & inhibitors | 3 | 75.0 |
Cell Line | 32 | 0.0 |
Escherichia coli/metabolism | 3 | 1.0 |
Hydrogen-Ion Concentration | 6 | 0.0 |
Recombinant Proteins | 4 | 0.0 |
Androgen Antagonists/*therapeutic use | 2 | 5.0 |
Anilides/*therapeutic use | 2 | 33.0 |
Levodopa/*diagnostic use | 7 | 77.0 |
Fertility/*physiology | 3 | 20.0 |
Follicle Stimulating Hormone/*blood | 43 | 56.0 |
Infertility, Female/*blood | 2 | 33.0 |
Luteinizing Hormone/blood | 249 | 45.0 |
Androstenedione/blood | 16 | 9.0 |
Angiotensin-Converting Enzyme Inhibitors/*pharmacology | 2 | 1.0 |
Dehydroepiandrosterone Sulfate/blood | 5 | 5.0 |
Gonadotropins/blood | 9 | 28.0 |
Polycystic Ovary Syndrome/*blood/complications | 2 | 25.0 |
Prospective Studies | 42 | 1.0 |
Sex Hormone-Binding Globulin/metabolism | 11 | 3.0 |
Testosterone/blood | 103 | 17.0 |
Body Temperature/physiology | 2 | 8.0 |
Body Temperature Regulation/*physiology | 2 | 8.0 |
Diet | 2 | 0.0 |
Energy Metabolism/physiology | 2 | 3.0 |
Fatty Acids, Nonesterified/blood | 2 | 1.0 |
*Heat | 2 | 1.0 |
Hyperprolactinemia/*physiopathology | 14 | 93.0 |
Neurons/physiology | 3 | 2.0 |
Serotonin/physiology | 7 | 24.0 |
Cohort Studies | 12 | 0.0 |
Immunoassay/*methods | 2 | 2.0 |
Medical Records | 2 | 2.0 |
Adenoma/complications/diagnosis | 2 | 100.0 |
Chromatography | 2 | 1.0 |
Molecular Weight | 40 | 1.0 |
Pituitary Gland/pathology | 8 | 34.0 |
Pituitary Neoplasms/complications/diagnosis | 5 | 100.0 |
Prolactin/*blood/*chemistry | 2 | 100.0 |
Protirelin/pharmacology | 79 | 68.0 |
Reference Values | 101 | 2.0 |
Prolactin/*physiology | 26 | 65.0 |
Estradiol/*analogs & derivatives/pharmacology | 3 | 6.0 |
Gene Expression Regulation | 8 | 0.0 |
Rats, Inbred F344 | 5 | 1.0 |
Rats, Inbred WF | 4 | 19.0 |
Hyperprolactinemia/*blood/immunology | 2 | 100.0 |
Polyethylene Glycols | 7 | 8.0 |
Precipitin Tests | 10 | 0.0 |
Reproducibility of Results | 7 | 0.0 |
Analysis of Variance | 27 | 1.0 |
Dihydrotestosterone/blood | 9 | 12.0 |
Double-Blind Method | 59 | 3.0 |
Hydrocortisone/blood | 101 | 24.0 |
Pituitary Gland/*drug effects | 6 | 42.0 |
Thyroid Hormones/blood | 19 | 19.0 |
Antipsychotic Agents/pharmacology/*therapeutic use | 2 | 40.0 |
Schizophrenia/*drug therapy | 6 | 18.0 |
Autoantibodies/*blood | 10 | 3.0 |
Hyperprolactinemia/*immunology | 9 | 100.0 |
Lupus Erythematosus, Systemic/blood/*immunology | 2 | 5.0 |
Prolactin/blood/*immunology | 3 | 100.0 |
Amenorrhea/drug therapy/etiology | 5 | 100.0 |
Dopamine Agonists/adverse effects/*therapeutic use | 3 | 100.0 |
Galactorrhea/drug therapy/etiology | 3 | 100.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 83 | 0.0 |
Visual Fields | 2 | 3.0 |
Blood-Brain Barrier/physiology | 2 | 7.0 |
Dimerization | 2 | 0.0 |
Hyperprolactinemia/*blood | 17 | 94.0 |
Macromolecular Substances | 8 | 0.0 |
Precipitation | 4 | 2.0 |
*Body Mass Index | 2 | 2.0 |
Obesity/*metabolism | 2 | 2.0 |
Prolactin/blood/*secretion | 159 | 95.0 |
Blotting, Western | 18 | 0.0 |
Cell Differentiation/drug effects | 8 | 0.0 |
Enzyme Inhibitors/pharmacology | 5 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 11 | 0.0 |
Interleukin-4/pharmacology | 3 | 0.0 |
Autoantibodies/*immunology | 3 | 1.0 |
Organ Specificity | 5 | 0.0 |
*Gene Expression Regulation | 4 | 0.0 |
Prolactin/*metabolism | 46 | 76.0 |
*Signal Transduction | 11 | 0.0 |
Gene Expression Profiling | 3 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 10 | 1.0 |
Receptors, Prolactin/chemistry/*metabolism | 2 | 100.0 |
DNA-Binding Proteins/metabolism | 9 | 0.0 |
*Intracellular Signaling Peptides and Proteins | 2 | 0.0 |
*Proto-Oncogene Proteins | 15 | 0.0 |
*Repressor Proteins | 4 | 0.0 |
Signal Transduction/*physiology | 5 | 0.0 |
Trans-Activators/metabolism | 6 | 0.0 |
*Transcription Factors | 4 | 0.0 |
Bromocriptine/adverse effects/*therapeutic use | 8 | 100.0 |
Drug Resistance | 20 | 3.0 |
Ergolines/adverse effects/*therapeutic use | 8 | 100.0 |
RNA, Messenger/drug effects/metabolism | 2 | 1.0 |
Bromocriptine/pharmacology | 43 | 78.0 |
Dopamine Agonists/*pharmacology | 3 | 25.0 |
Exocytosis | 2 | 2.0 |
Microscopy, Immunoelectron | 3 | 0.0 |
Prolactin/analysis/blood | 2 | 66.0 |
Subcellular Fractions/metabolism | 3 | 0.0 |
Biological Assay | 31 | 11.0 |
Immunoradiometric Assay | 18 | 17.0 |
Lymphoma | 4 | 10.0 |
Prevalence | 5 | 0.0 |
Tumor Cells, Cultured | 51 | 0.0 |
Calcium/*metabolism | 2 | 0.0 |
Cytoplasm/metabolism | 2 | 0.0 |
Enzyme Activation | 4 | 0.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors/*metabolism | 2 | 3.0 |
Blood Glucose/analysis | 19 | 2.0 |
Cross-Sectional Studies | 8 | 0.0 |
*Fertility | 7 | 36.0 |
Insulin/blood | 22 | 3.0 |
Insulin-Like Growth Factor I/analysis | 18 | 13.0 |
Metoclopramide/*pharmacology | 23 | 67.0 |
Obesity/blood | 4 | 11.0 |
Human Growth Hormone/secretion | 8 | 34.0 |
Insulin/secretion | 4 | 7.0 |
Somatotropin-Releasing Hormone/secretion | 2 | 40.0 |
Blood Glucose | 3 | 3.0 |
Circadian Rhythm/*physiology | 12 | 12.0 |
Exercise/*physiology | 8 | 2.0 |
Hormones/*blood | 31 | 21.0 |
Aged, 80 and over | 36 | 0.0 |
Prolactin/blood/drug effects | 3 | 100.0 |
Prolactinoma/*drug therapy/pathology/*surgery | 2 | 100.0 |
Autoantibodies/blood | 5 | 2.0 |
DNA/immunology | 4 | 8.0 |
Hyperprolactinemia/*etiology | 9 | 100.0 |
Immunosuppressive Agents/therapeutic use | 2 | 0.0 |
Postmenopause | 5 | 2.0 |
Gene Expression/physiology | 2 | 0.0 |
Growth Hormone/*physiology | 2 | 7.0 |
Hyperplasia | 8 | 2.0 |
Metallothionein/genetics | 2 | 5.0 |
Mice, Inbred Strains | 2 | 0.0 |
Mice, Knockout/genetics | 2 | 5.0 |
Phenotype | 8 | 0.0 |
Pituitary Neoplasms/*etiology | 2 | 66.0 |
Somatotropin-Releasing Hormone/*pharmacology | 20 | 20.0 |
Transgenes/genetics | 2 | 2.0 |
Receptor, Serotonin, 5-HT2A | 3 | 7.0 |
Receptors, Serotonin/*drug effects | 5 | 55.0 |
Risperidone/*therapeutic use | 2 | 40.0 |
Schizophrenia/*drug therapy/metabolism | 2 | 50.0 |
Androgens/physiology | 2 | 4.0 |
Cell Division/drug effects | 27 | 0.0 |
Culture Media, Conditioned | 5 | 1.0 |
Mice, Nude | 4 | 0.0 |
Molecular Mimicry | 4 | 5.0 |
Buspirone/*pharmacology | 2 | 100.0 |
Hydrocortisone/blood/*pharmacology | 2 | 40.0 |
Prolactin/blood/*metabolism | 13 | 100.0 |
Serotonin Agonists/*pharmacology | 5 | 50.0 |
Sex Characteristics | 14 | 2.0 |
Follicle Stimulating Hormone/blood | 241 | 45.0 |
Infertility, Male/blood/*physiopathology | 2 | 100.0 |
Iodide Peroxidase/immunology | 3 | 5.0 |
Sex Hormone-Binding Globulin/analysis | 13 | 4.0 |
Thyroid Gland/*physiopathology | 3 | 11.0 |
Thyrotropin/*blood | 69 | 56.0 |
Triiodothyronine/*blood | 3 | 10.0 |
Dose-Response Relationship, Immunologic | 3 | 0.0 |
Hyperprolactinemia/immunology | 2 | 100.0 |
Lactation/physiology | 4 | 26.0 |
Reproduction/physiology | 2 | 14.0 |
Lupus Erythematosus, Systemic/*immunology | 2 | 1.0 |
Adenoma/secretion/*ultrastructure | 2 | 100.0 |
Corticotropin/secretion | 13 | 21.0 |
Microscopy, Electron | 26 | 1.0 |
Pituitary Neoplasms/secretion/*ultrastructure | 2 | 100.0 |
Prolactin/secretion | 72 | 71.0 |
Thyrotropin/secretion | 28 | 70.0 |
Aminoquinolines/*therapeutic use | 7 | 58.0 |
Dopamine Agonists/*therapeutic use | 25 | 86.0 |
Lupus Erythematosus, Systemic/*drug therapy/immunology | 2 | 33.0 |
Cross-Over Studies | 11 | 1.0 |
Cyproheptadine/pharmacology | 3 | 75.0 |
Neurosecretory Systems/*drug effects | 8 | 72.0 |
Pilot Projects | 2 | 0.0 |
Serotonin Antagonists/pharmacology | 4 | 25.0 |
Disease Progression | 4 | 0.0 |
Drug Therapy, Combination | 26 | 1.0 |
Area Under Curve | 3 | 0.0 |
CD4 Lymphocyte Count | 2 | 0.0 |
Dopamine Antagonists/*diagnostic use | 4 | 80.0 |
Flow Cytometry | 6 | 0.0 |
Immunoblotting | 10 | 0.0 |
Metoclopramide/*diagnostic use | 14 | 82.0 |
Protein Isoforms/blood | 2 | 8.0 |
Regression Analysis | 17 | 1.0 |
Viral Load | 3 | 0.0 |
Base Sequence | 40 | 0.0 |
Gene Deletion | 3 | 0.0 |
Protein Isoforms/genetics | 2 | 0.0 |
Thymidine Kinase/genetics | 2 | 2.0 |
Schizophrenia/*blood/drug therapy | 10 | 52.0 |
Chromatography, Gel | 39 | 4.0 |
Lupus Erythematosus, Systemic/blood/*complications | 2 | 50.0 |
Polyethylene Glycols/*diagnostic use | 2 | 40.0 |
Ergolines/therapeutic use | 8 | 100.0 |
Fertility | 3 | 11.0 |
Menstruation | 19 | 30.0 |
Tomography, X-Ray Computed | 40 | 5.0 |
Lupus Erythematosus, Systemic/*blood/immunology | 2 | 10.0 |
Pregnancy/blood/*immunology | 2 | 50.0 |
*Pregnancy Complications | 2 | 5.0 |
Prolactin/*immunology | 7 | 100.0 |
Chorionic Gonadotropin/administration & dosage | 3 | 20.0 |
*Fertilization in Vitro | 17 | 16.0 |
Menotropins/administration & dosage | 2 | 40.0 |
Ovarian Follicle/anatomy & histology | 2 | 66.0 |
*Ovulation Induction | 11 | 26.0 |
Administration, Oral | 56 | 5.0 |
Circadian Rhythm | 51 | 20.0 |
Melatonin/administration & dosage/*pharmacology | 2 | 40.0 |
Antipsychotic Agents/*therapeutic use | 9 | 27.0 |
Benzodiazepines | 2 | 9.0 |
Drugs, Chinese Herbal/*therapeutic use | 2 | 2.0 |
Endometriosis/*drug therapy | 2 | 66.0 |
Corticosterone/blood | 3 | 8.0 |
*Gene Expression | 14 | 1.0 |
Promoter Regions (Genetics) | 17 | 0.0 |
Fenfluramine/pharmacology | 2 | 100.0 |
Piperazines/*pharmacology | 5 | 8.0 |
Prolactin/blood/*pharmacology | 4 | 100.0 |
Serotonin Uptake Inhibitors/pharmacology | 3 | 25.0 |
Estrogens/pharmacology | 5 | 5.0 |
Hypogonadism/*metabolism | 3 | 75.0 |
Body Mass Index | 8 | 0.0 |
Estrogens/blood | 17 | 34.0 |
*Hostility | 2 | 33.0 |
Neurotransmitters/*metabolism | 2 | 6.0 |
Serotonin/metabolism | 3 | 3.0 |
Glycosylation | 8 | 0.0 |
Human Growth Hormone/analysis | 2 | 50.0 |
Milk, Human/*chemistry | 2 | 4.0 |
Prolactin/analysis | 10 | 55.0 |
Rabbits | 26 | 0.0 |
*Circadian Rhythm | 30 | 14.0 |
Hydrocortisone/*secretion | 8 | 33.0 |
Schizophrenia/*physiopathology | 4 | 26.0 |
Aminoquinolines/therapeutic use | 5 | 100.0 |
Antineoplastic Agents, Hormonal/*therapeutic use | 5 | 6.0 |
Corticotropin/analysis | 7 | 30.0 |
Follicle Stimulating Hormone/analysis | 9 | 56.0 |
Growth Hormone/analysis | 5 | 45.0 |
Luteinizing Hormone/analysis | 7 | 58.0 |
Receptors, Dopamine/metabolism | 7 | 50.0 |
Receptors, Somatostatin/metabolism | 3 | 16.0 |
Thyrotropin/analysis | 5 | 41.0 |
Tumor Cells, Cultured/drug effects/metabolism | 2 | 1.0 |
Chromatography, Affinity | 8 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 15 | 0.0 |
Immunoglobulin G/blood | 4 | 1.0 |
Rats, Sprague-Dawley | 19 | 0.0 |
Bromocriptine/*therapeutic use | 62 | 92.0 |
CD4-CD8 Ratio | 2 | 0.0 |
HLA-DR Antigens/analysis | 2 | 0.0 |
Killer Cells, Natural/immunology | 3 | 0.0 |
Lymphocytes/immunology | 2 | 0.0 |
Binding Sites | 21 | 0.0 |
Blood Platelets/metabolism | 2 | 1.0 |
Brain/*metabolism | 3 | 0.0 |
Cell Nucleus/metabolism | 3 | 0.0 |
*Exercise | 4 | 2.0 |
Models, Biological | 11 | 0.0 |
Protein Binding | 10 | 0.0 |
Serotonin/*metabolism | 2 | 4.0 |
Pituitary Neoplasms/*blood | 16 | 84.0 |
Prolactin/*blood/*immunology | 2 | 100.0 |
Prolactinoma/*blood | 8 | 88.0 |
Acromegaly/metabolism | 6 | 46.0 |
Adenoma/*metabolism/secretion | 2 | 22.0 |
Pituitary Neoplasms/*metabolism/secretion | 4 | 36.0 |
Prolactinoma/metabolism | 5 | 38.0 |
RNA, Messenger/*analysis | 8 | 1.0 |
Glycoprotein Hormones, alpha Subunit/*blood | 2 | 66.0 |
Pedigree | 8 | 0.0 |
Pituitary Gland/*pathology | 11 | 64.0 |
Prolactin/blood/secretion | 22 | 91.0 |
Pulsatile Flow | 11 | 25.0 |
Lithium Carbonate/*therapeutic use | 2 | 100.0 |
Neuroimmunomodulation | 2 | 10.0 |
Cell Differentiation/physiology | 3 | 0.0 |
Killer Cells, Natural/*immunology | 2 | 0.0 |
Decidua/*physiology | 8 | 44.0 |
Sequence Deletion | 2 | 0.0 |
Transcription Factors/metabolism | 3 | 0.0 |
Transfection | 23 | 0.0 |
Blood Platelets/*metabolism | 2 | 0.0 |
Depressive Disorder, Major/*blood | 2 | 66.0 |
Hydrocortisone/*blood | 34 | 24.0 |
Serotonin/*blood | 4 | 28.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Thyroxine/blood | 51 | 19.0 |
Dopamine Agonists/pharmacology | 5 | 27.0 |
Lactation/*drug effects | 17 | 94.0 |
Postpartum Period/*physiology | 7 | 58.0 |
Brain/physiology | 2 | 3.0 |
Immunoglobulins/blood | 2 | 2.0 |
Anti-HIV Agents/therapeutic use | 2 | 0.0 |
Cell Line, Tumor | 9 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Protein-Serine-Threonine Kinases/*metabolism | 2 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 3 | 0.0 |
RNA, Messenger/genetics | 6 | 0.0 |
Hyperprolactinemia/complications | 5 | 100.0 |
Leukocytes, Mononuclear/*metabolism | 2 | 1.0 |
Growth Hormone/metabolism | 10 | 23.0 |
Prolactin/metabolism | 30 | 53.0 |
Hormone Antagonists/*therapeutic use | 3 | 27.0 |
Hyperprolactinemia/*drug therapy/etiology | 4 | 100.0 |
Bromocriptine/administration & dosage | 6 | 85.0 |
Dopamine Antagonists/administration & dosage | 2 | 100.0 |
Infusions, Intravenous | 21 | 3.0 |
Labor, Obstetric/*physiology | 3 | 20.0 |
Metoclopramide/administration & dosage | 2 | 100.0 |
Periodicity | 7 | 14.0 |
Injections, Intraventricular | 4 | 2.0 |
Parity | 6 | 5.0 |
Receptors, Prolactin/*antagonists & inhibitors | 2 | 100.0 |
Pregnancy Trimester, Second | 6 | 2.0 |
Pregnancy Trimester, Third | 12 | 6.0 |
Antibodies, Antinuclear/blood | 7 | 14.0 |
Calcium/metabolism | 6 | 0.0 |
Chorionic Gonadotropin/metabolism | 5 | 16.0 |
Sheep | 22 | 3.0 |
Hyperprolactinemia/*metabolism | 5 | 100.0 |
Leydig Cells/drug effects/*metabolism | 2 | 28.0 |
Testosterone/*biosynthesis | 4 | 20.0 |
Corticotropin/*deficiency | 9 | 50.0 |
Genetic Markers | 2 | 0.0 |
Homeodomain Proteins/*genetics | 3 | 0.0 |
Homozygote | 2 | 0.0 |
Hypopituitarism/*genetics | 3 | 60.0 |
Molecular Sequence Data | 47 | 0.0 |
Pituitary Hormones/*deficiency | 5 | 29.0 |
Transcription Factors/*genetics | 8 | 0.0 |
Corticotropin/*pharmacology | 4 | 23.0 |
Gene Expression Regulation/*drug effects | 6 | 0.0 |
RNA, Messenger/analysis | 12 | 0.0 |
Stromal Cells/metabolism | 2 | 2.0 |
Pituitary Hormones/secretion | 3 | 50.0 |
Coculture Techniques | 2 | 0.0 |
Mammals | 2 | 0.0 |
RNA, Messenger/metabolism | 19 | 0.0 |
Signal Transduction/physiology | 2 | 0.0 |
Triiodothyronine/pharmacology | 5 | 10.0 |
Apoptosis/drug effects | 3 | 0.0 |
Prolactin/metabolism/pharmacology | 2 | 33.0 |
Seasons | 3 | 2.0 |
Spermatogenesis/*drug effects | 3 | 37.0 |
Bromocriptine/*pharmacology/therapeutic use | 7 | 87.0 |
Gonadorelin/*pharmacology | 15 | 42.0 |
Adenoma/*complications/metabolism/pathology | 2 | 100.0 |
Pituitary Neoplasms/*complications/metabolism/pathology | 2 | 100.0 |
Acromegaly/blood/*drug therapy | 5 | 35.0 |
Dopamine Agonists/*administration & dosage | 3 | 100.0 |
Drug Synergism | 12 | 0.0 |
Ergolines/*administration & dosage | 3 | 100.0 |
Octreotide/administration & dosage | 3 | 50.0 |
Antibodies, Monoclonal | 8 | 0.0 |
DNA/biosynthesis | 6 | 1.0 |
Immunoassay | 4 | 1.0 |
Insulin-Like Growth Factor I/pharmacology | 7 | 3.0 |
Recombinant Proteins/pharmacology | 16 | 0.0 |
DNA Primers | 3 | 0.0 |
DNA-Binding Proteins/*genetics | 7 | 0.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Prolactin/genetics | 4 | 23.0 |
Ergolines/administration & dosage/adverse effects/*therapeutic use | 6 | 100.0 |
Body Weight/drug effects | 6 | 3.0 |
Dopamine Antagonists/pharmacology | 5 | 35.0 |
Genes, Reporter | 4 | 0.0 |
Haloperidol/pharmacology | 6 | 28.0 |
Mammary Neoplasms, Experimental/*chemically induced | 2 | 50.0 |
Ovariectomy | 7 | 5.0 |
Random Allocation | 19 | 4.0 |
Reserpine/pharmacology | 3 | 42.0 |
Trans-Activation (Genetics) | 4 | 0.0 |
Uterus/drug effects | 2 | 20.0 |
Corticotropin/blood | 32 | 19.0 |
Epinephrine/blood | 11 | 9.0 |
Neurosecretory Systems/*physiopathology | 4 | 23.0 |
Norepinephrine/blood | 9 | 4.0 |
Stress, Psychological/*blood | 2 | 40.0 |
Apoptosis | 3 | 0.0 |
Cell Division | 15 | 0.0 |
Enzyme Activation/drug effects | 4 | 0.0 |
Interleukin-3/pharmacology | 2 | 0.0 |
Mutation | 7 | 0.0 |
Structure-Activity Relationship | 4 | 0.0 |
Multivariate Analysis | 5 | 0.0 |
Neoplasm Recurrence, Local | 3 | 0.0 |
Neoplasm Staging | 6 | 0.0 |
Prolactin/*biosynthesis/blood/genetics | 2 | 100.0 |
RNA, Messenger/biosynthesis/genetics | 3 | 0.0 |
Aminoquinolines/adverse effects/*therapeutic use | 12 | 100.0 |
Hyperprolactinemia/*drug therapy | 19 | 100.0 |
Pituitary Neoplasms/blood | 24 | 85.0 |
Placebos | 18 | 7.0 |
Prolactinoma/blood | 4 | 80.0 |
Delayed-Action Preparations | 27 | 26.0 |
Dopamine Agonists/therapeutic use | 8 | 66.0 |
Hormones/blood | 12 | 11.0 |
Octreotide/*therapeutic use | 5 | 13.0 |
Pituitary Neoplasms/*drug therapy | 14 | 73.0 |
Prolactinoma/*drug therapy | 9 | 100.0 |
Mice, Inbred ICR | 2 | 0.0 |
Prolactin/blood/metabolism | 4 | 100.0 |
Receptors, Estrogen/metabolism | 3 | 1.0 |
Receptors, Progesterone/metabolism | 2 | 1.0 |
Cytokines/physiology | 2 | 1.0 |
Neurosecretory Systems/physiology | 2 | 14.0 |
Cytokines/*pharmacology | 3 | 0.0 |
*DNA-Binding Proteins | 2 | 0.0 |
Growth Hormone/*pharmacology | 8 | 10.0 |
Leukemia/*metabolism | 2 | 4.0 |
*Trans-Activators | 2 | 0.0 |
Antipsychotic Agents/*pharmacology | 2 | 8.0 |
Estrogens/*pharmacology | 6 | 7.0 |
Indicators and Reagents | 2 | 0.0 |
Pituitary Hormones, Anterior/blood | 13 | 81.0 |
Sulpiride/*pharmacology | 12 | 92.0 |
Transcription, Genetic/*genetics | 2 | 1.0 |
Puberty | 10 | 13.0 |
Hypothalamo-Hypophyseal System/*physiopathology | 22 | 43.0 |
Acute Disease | 18 | 0.0 |
Adrenal Cortex Hormones/*blood | 5 | 29.0 |
Dehydroepiandrosterone Sulfate | 20 | 20.0 |
Gonadotropins, Pituitary/*blood | 31 | 57.0 |
Ovary/drug effects | 4 | 26.0 |
Pituitary-Adrenal System/drug effects | 3 | 50.0 |
Testis/drug effects | 3 | 37.0 |
beta-Endorphin/*blood | 4 | 28.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Follicle Stimulating Hormone/secretion | 24 | 85.0 |
Human Growth Hormone/*deficiency | 3 | 14.0 |
Luteinizing Hormone/secretion | 28 | 65.0 |
Lymphocytes | 2 | 1.0 |
Prolactin/*deficiency | 3 | 100.0 |
Thyrotropin/*deficiency | 2 | 66.0 |
Transcription Factors/genetics | 3 | 0.0 |
In Vitro | 29 | 0.0 |
Prolactin/*metabolism/pharmacology | 3 | 60.0 |
Rats, Wistar | 11 | 0.0 |
Growth Hormone/pharmacology | 5 | 14.0 |
Interleukin-2/pharmacology | 3 | 0.0 |
Prolactin/genetics/*metabolism/pharmacology | 2 | 100.0 |
Pituitary Neoplasms/blood/*drug therapy/pathology | 3 | 100.0 |
Prolactinoma/blood/*drug therapy/pathology | 3 | 100.0 |
Receptors, Dopamine D2/*agonists | 2 | 66.0 |
Growth Hormone/*biosynthesis/secretion | 2 | 66.0 |
Insulin-Like Growth Factor I/*pharmacology | 3 | 2.0 |
Insulin-Like Growth Factor II/pharmacology | 2 | 8.0 |
Pituitary Gland/*metabolism | 7 | 18.0 |
Prolactin/*biosynthesis/secretion | 5 | 83.0 |
Ergolines/*therapeutic use | 34 | 100.0 |
Prolactin/blood/physiology | 2 | 100.0 |
Aging/*metabolism | 3 | 1.0 |
Injections, Subcutaneous | 4 | 1.0 |
Breast Feeding | 10 | 16.0 |
*Prolactin | 2 | 100.0 |
Pituitary Gland/*physiopathology | 18 | 64.0 |
Antibodies, Monoclonal/pharmacology | 3 | 0.0 |
Cattle | 25 | 0.0 |
Stimulation, Chemical | 34 | 6.0 |
Umbilical Veins | 5 | 1.0 |
Amenorrhea/chemically induced | 2 | 66.0 |
Androgens/blood | 8 | 11.0 |
Blood Pressure | 7 | 1.0 |
Hydrocortisone/blood/urine | 2 | 16.0 |
Libido/drug effects | 5 | 45.0 |
Premenopause | 3 | 3.0 |
Gonadal Steroid Hormones/*blood | 19 | 12.0 |
*Kidney Transplantation | 7 | 1.0 |
CA-15-3 Antigen/blood | 2 | 15.0 |
Tumor Markers, Biological/*blood | 3 | 0.0 |
Adenoma/pathology/*secretion | 4 | 50.0 |
Diagnosis, Differential | 32 | 1.0 |
Pituitary Neoplasms/pathology/*secretion | 5 | 50.0 |
Algorithms | 2 | 0.0 |
Amino Acid Sequence | 28 | 0.0 |
Conserved Sequence | 3 | 0.0 |
Models, Molecular | 4 | 0.0 |
Syndrome | 13 | 0.0 |
Dopamine/*metabolism | 5 | 4.0 |
Blotting, Northern | 17 | 0.0 |
CHO Cells | 8 | 0.0 |
Hamsters | 17 | 0.0 |
Thyrotropin/metabolism | 6 | 10.0 |
Neoplasm Metastasis | 4 | 0.0 |
Prolactin/drug effects/*secretion | 4 | 80.0 |
Benzamides/diagnostic use | 2 | 66.0 |
Iodine Radioisotopes/diagnostic use | 5 | 1.0 |
Predictive Value of Tests | 13 | 0.0 |
Prolactin/*blood/genetics | 2 | 100.0 |
Dopamine Agents/*therapeutic use | 5 | 55.0 |
Questionnaires | 2 | 0.0 |
Protirelin/blood | 5 | 50.0 |
Combined Modality Therapy | 12 | 1.0 |
Recurrence | 7 | 0.0 |
Blood Pressure/drug effects | 16 | 2.0 |
Heart Rate/drug effects | 5 | 2.0 |
Hemodynamic Processes/*drug effects | 2 | 1.0 |
Injections, Intravenous | 48 | 7.0 |
Bone Density/drug effects | 2 | 7.0 |
Longitudinal Studies | 11 | 1.0 |
Corticotropin/pharmacology | 9 | 16.0 |
Histocytochemistry | 6 | 0.0 |
Progesterone/metabolism | 5 | 6.0 |
Receptors, LH/genetics/*metabolism | 2 | 25.0 |
Steroids/*biosynthesis | 2 | 3.0 |
Blotting, Southern | 4 | 0.0 |
Breast Neoplasms/*metabolism | 2 | 0.0 |
Protein Isoforms | 2 | 0.0 |
Receptors, Prolactin/*genetics/*metabolism | 2 | 66.0 |
Calcium/blood | 9 | 4.0 |
Immunodiffusion | 3 | 1.0 |
Hyperprolactinemia/etiology | 6 | 85.0 |
Fluorescent Antibody Technique | 5 | 0.0 |
Prolactin/genetics/*metabolism | 4 | 100.0 |
Anorexia Nervosa/*blood | 5 | 29.0 |
Galanin/*pharmacology | 2 | 40.0 |
Human Growth Hormone/*blood | 4 | 13.0 |
Somatotropin-Releasing Hormone/pharmacology | 8 | 16.0 |
Antipsychotic Agents/adverse effects/*therapeutic use | 2 | 18.0 |
Brain Mapping | 2 | 1.0 |
Contrast Media | 2 | 3.0 |
Psychiatric Status Rating Scales | 22 | 10.0 |
Acromegaly/etiology | 4 | 57.0 |
Human Growth Hormone/blood/secretion | 2 | 40.0 |
*Radiosurgery | 3 | 25.0 |
Phosphoproteins/*genetics | 2 | 0.0 |
Hostility | 2 | 50.0 |
Hydrocortisone/metabolism | 3 | 9.0 |
Personality Inventory | 3 | 8.0 |
Substance-Related Disorders/*metabolism | 2 | 28.0 |
Alcoholism/*physiopathology/rehabilitation | 2 | 100.0 |
Brain/physiopathology | 2 | 3.0 |
Ethanol/*adverse effects | 2 | 8.0 |
Haloperidol/*diagnostic use | 2 | 100.0 |
Receptors, Dopamine/*physiology | 6 | 54.0 |
Amenorrhea/etiology | 13 | 81.0 |
Galactorrhea/etiology | 11 | 100.0 |
Infertility, Female/etiology | 4 | 40.0 |
Pituitary Neoplasms/complications/*diagnosis | 3 | 100.0 |
Electromyography | 2 | 1.0 |
Haloperidol/*therapeutic use | 3 | 75.0 |
Injections | 5 | 4.0 |
Antineoplastic Agents/therapeutic use | 3 | 1.0 |
*Critical Illness | 5 | 26.0 |
Gonadal Steroid Hormones/blood | 14 | 20.0 |
Insulin-Like Growth Factor I/*metabolism | 2 | 1.0 |
Genes, Reporter/genetics | 2 | 0.0 |
Luciferases/genetics | 2 | 0.0 |
Pituitary Gland/cytology/*metabolism | 3 | 30.0 |
Polymerase Chain Reaction | 16 | 0.0 |
Hypothalamo-Hypophyseal System/drug effects | 6 | 35.0 |
Pituitary Hormones, Anterior/*blood | 25 | 75.0 |
Spermatogenesis/drug effects | 2 | 14.0 |
Dopamine/biosynthesis | 2 | 20.0 |
Mice, Knockout | 2 | 0.0 |
Receptors, Prolactin/genetics/*physiology | 3 | 100.0 |
Receptors, Neuropeptide/*genetics | 2 | 9.0 |
Glucocorticoids/therapeutic use | 2 | 2.0 |
Hormones/*physiology | 4 | 9.0 |
Neurosecretory Systems/*physiology | 3 | 11.0 |
Lipids/*blood | 4 | 0.0 |
Menopause/blood | 2 | 11.0 |
Peptide Fragments/blood | 3 | 2.0 |
Procollagen/blood | 2 | 6.0 |
Hyperprolactinemia/*blood/etiology | 2 | 66.0 |
Prolactinoma/blood/*complications | 2 | 100.0 |
Infertility, Female/*physiopathology | 2 | 50.0 |
Prolactin/*genetics/metabolism | 4 | 66.0 |
Menstrual Cycle/*physiology | 6 | 11.0 |
Prolactin/analysis/*pharmacology | 2 | 100.0 |
RNA Probes | 2 | 1.0 |
Lymphoma, T-Cell | 2 | 10.0 |
Mutagenesis | 2 | 0.0 |
Phosphotyrosine/metabolism | 2 | 0.0 |
Protein-Tyrosine Kinase/*metabolism | 3 | 0.0 |
Hyperprolactinemia/*complications | 6 | 100.0 |
Pregnancy, Animal/*metabolism | 3 | 20.0 |
Receptors, Prolactin/*genetics | 4 | 23.0 |
Adenoma/*secretion | 17 | 65.0 |
Octreotide/pharmacology | 3 | 12.0 |
Pituitary Neoplasms/*secretion | 32 | 74.0 |
Prolactinoma/*secretion | 4 | 100.0 |
Protirelin/*diagnostic use | 65 | 77.0 |
Fluoroimmunoassay | 4 | 9.0 |
Fractional Precipitation | 2 | 28.0 |
Glucose Tolerance Test | 10 | 2.0 |
Hydrocortisone/urine | 2 | 16.0 |
Obesity/*blood | 6 | 7.0 |
Hyperprolactinemia/blood/complications | 3 | 100.0 |
Immunoenzyme Techniques | 14 | 0.0 |
Prolactin/biosynthesis/*genetics | 2 | 50.0 |
Bromocriptine/administration & dosage/*therapeutic use | 11 | 91.0 |
Hyperthyroidism/etiology | 2 | 100.0 |
Pituitary Neoplasms/diagnosis/drug therapy/*secretion | 2 | 100.0 |
Protirelin/diagnostic use | 105 | 72.0 |
Somatotropin-Releasing Hormone/diagnostic use | 2 | 8.0 |
Thyrotropin/*secretion | 25 | 69.0 |
Postoperative Complications | 2 | 1.0 |
Biopsy | 5 | 0.0 |
Luteinizing Hormone/*blood | 59 | 56.0 |
Testis/*pathology | 2 | 15.0 |
Testosterone/*blood | 30 | 10.0 |
Mutagenesis, Site-Directed | 8 | 0.0 |
Point Mutation | 5 | 0.0 |
Recombinant Proteins/drug effects/genetics/metabolism | 2 | 12.0 |
Bromocriptine/adverse effects/therapeutic use | 10 | 100.0 |
Drug Tolerance | 13 | 10.0 |
Antineoplastic Agents/administration & dosage/*therapeutic use | 3 | 17.0 |
Ergolines/administration & dosage/*therapeutic use | 5 | 100.0 |
Pituitary Neoplasms/*drug therapy/pathology | 5 | 100.0 |
Pregnancy Complications, Neoplastic | 2 | 66.0 |
Prolactinoma/*drug therapy/pathology | 4 | 100.0 |
Fenfluramine/*pharmacology | 12 | 70.0 |
Serotonin Uptake Inhibitors/*pharmacology | 4 | 13.0 |
Spectrum Analysis, Mass/methods | 2 | 5.0 |
Disease Models, Animal | 5 | 0.0 |
Protein Conformation | 6 | 0.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
Hormone Antagonists/*pharmacology | 4 | 16.0 |
Hysterectomy | 4 | 5.0 |
Leiomyoma/*metabolism | 2 | 12.0 |
Adenoma/*drug therapy/pathology/secretion | 2 | 100.0 |
Antineoplastic Agents/*therapeutic use | 7 | 1.0 |
Drug Resistance, Neoplasm | 2 | 0.0 |
Pituitary Neoplasms/*drug therapy/pathology/secretion | 4 | 100.0 |
Naloxone/diagnostic use | 3 | 60.0 |
Thyrotropin/blood/*secretion | 14 | 66.0 |
Emotions/*drug effects | 2 | 50.0 |
Glucocorticoids/*pharmacology | 2 | 1.0 |
Receptors, Serotonin/drug effects | 2 | 40.0 |
Lactation/*physiology | 10 | 55.0 |
Menstrual Cycle/physiology | 2 | 5.0 |
Breast/*physiology | 4 | 40.0 |
Mammary Glands, Animal/*physiology | 2 | 25.0 |
Pituitary Gland/secretion | 7 | 58.0 |
Prolactin/*physiology/secretion | 2 | 66.0 |
Hyperprolactinemia/blood/*diagnosis | 5 | 100.0 |
Cluster Analysis | 2 | 1.0 |
Pituitary Neoplasms/blood/*secretion | 6 | 85.0 |
Immunohistochemistry/methods | 3 | 0.0 |
Octreotide/therapeutic use | 3 | 23.0 |
Staining and Labeling | 4 | 0.0 |
Thyrotropin/*metabolism | 3 | 13.0 |
Cell Division/physiology | 3 | 0.0 |
Iodine Radioisotopes | 9 | 2.0 |
Receptors, Prolactin/genetics/*metabolism | 2 | 33.0 |
Up-Regulation | 2 | 0.0 |
*Seasons | 3 | 7.0 |
Serotonin Agents/*pharmacology | 2 | 100.0 |
Gonadorelin/diagnostic use | 38 | 64.0 |
Gonadotropins, Pituitary/blood | 12 | 35.0 |
Hypogonadism/*complications | 2 | 50.0 |
Karyotyping | 2 | 0.0 |
Amino Acids/*blood | 2 | 10.0 |
Osmolar Concentration | 25 | 3.0 |
Physical Endurance/physiology | 3 | 9.0 |
Tryptophan/blood | 3 | 37.0 |
Aging/*blood | 4 | 5.0 |
Oligopeptides/*therapeutic use | 3 | 17.0 |
DNA/metabolism | 3 | 0.0 |
DNA-Binding Proteins/*genetics/metabolism | 3 | 0.0 |
Hypothyroidism/metabolism | 3 | 23.0 |
*Mutation | 8 | 0.0 |
Transcription Factors/*genetics/metabolism | 2 | 0.0 |
Cervix Uteri/*physiology | 2 | 50.0 |
Chorionic Gonadotropin/blood | 10 | 10.0 |
Blood Glucose/drug effects | 2 | 10.0 |
Fetus | 4 | 0.0 |
*Pituitary Neoplasms | 2 | 66.0 |
Somatostatin/*analogs & derivatives/*pharmacology | 2 | 22.0 |
Magnetic Resonance Imaging/methods | 2 | 2.0 |
Decidua/*metabolism | 11 | 28.0 |
Endometrium/metabolism | 5 | 9.0 |
Adenoma/radiography | 2 | 100.0 |
Estradiol/administration & dosage | 3 | 25.0 |
Hyperprolactinemia/*blood/drug therapy | 3 | 100.0 |
Pituitary Neoplasms/radiography | 2 | 100.0 |
Estradiol/analysis | 2 | 10.0 |
*Menstrual Cycle | 18 | 29.0 |
Progesterone/analysis | 2 | 10.0 |
Prolactin/*analysis | 13 | 86.0 |
Pituitary Gland/chemistry | 5 | 22.0 |
Cell Survival/drug effects | 2 | 0.0 |
Prolactin/pharmacology | 8 | 21.0 |
Bromocriptine/*pharmacology | 28 | 80.0 |
Growth Hormone/*secretion | 51 | 43.0 |
Neoplasm Transplantation | 7 | 0.0 |
Pituitary Neoplasms/*pathology/secretion | 3 | 75.0 |
*Renal Dialysis | 9 | 2.0 |
Hypothalamo-Hypophyseal System/*physiology | 6 | 25.0 |
Pituitary Neoplasms/complications/radiography | 3 | 75.0 |
Receptors, Prolactin/*antagonists & inhibitors/chemistry | 2 | 100.0 |
Adenoma/*metabolism | 6 | 10.0 |
Estrogen Receptor alpha | 2 | 0.0 |
Exons | 3 | 0.0 |
Pituitary Neoplasms/*metabolism | 8 | 22.0 |
RNA, Messenger/biosynthesis | 6 | 0.0 |
Clinical Trials | 31 | 3.0 |
Hypophysectomy/methods | 2 | 100.0 |
DNA, Complementary | 3 | 0.0 |
Rats/*genetics | 2 | 3.0 |
Sequence Homology, Nucleic Acid | 7 | 0.0 |
*Transcription, Genetic | 4 | 0.0 |
Endocrine Glands/*physiopathology | 2 | 20.0 |
Hypopituitarism/etiology | 2 | 66.0 |
Postoperative Period | 11 | 3.0 |
Pituitary Neoplasms/drug therapy | 5 | 100.0 |
Bromocriptine/*administration & dosage | 13 | 100.0 |
Hormone Antagonists/*administration & dosage | 3 | 60.0 |
Prolactin/antagonists & inhibitors/*blood | 4 | 80.0 |
Lupus Erythematosus, Systemic/*blood/*immunology | 2 | 25.0 |
Lupus Erythematosus, Systemic/*blood | 4 | 13.0 |
Peptide Fragments/*pharmacology | 6 | 3.0 |
Galactorrhea | 3 | 100.0 |
Growth Disorders/etiology | 2 | 20.0 |
Pyrrolidonecarboxylic Acid/analogs & derivatives | 3 | 12.0 |
Brazil | 3 | 1.0 |
*Consanguinity | 2 | 8.0 |
Follicle Stimulating Hormone/deficiency | 2 | 50.0 |
Human Growth Hormone/deficiency | 2 | 28.0 |
Luteinizing Hormone/deficiency | 2 | 50.0 |
Prolactin/deficiency | 3 | 75.0 |
Thyrotropin/deficiency | 4 | 57.0 |
Growth Hormone/*blood | 96 | 54.0 |
Sleep/*physiology | 12 | 23.0 |
Serotonin/*physiology | 12 | 46.0 |
Single-Blind Method | 3 | 1.0 |
Prolactin/blood/cerebrospinal fluid/*metabolism | 2 | 100.0 |
Levodopa/*pharmacology | 9 | 52.0 |
Polycystic Ovary Syndrome/*blood | 9 | 36.0 |
Interleukin-6/pharmacology | 2 | 0.0 |
Growth Substances/pharmacology | 3 | 1.0 |
Oligopeptides/*pharmacology | 8 | 9.0 |
Protirelin/diagnostic use/*pharmacology | 3 | 75.0 |
Amino Acids, Branched-Chain/*pharmacology | 2 | 66.0 |
Exercise Test | 5 | 1.0 |
Tyrosine/*pharmacology | 2 | 40.0 |
*Aromatase Inhibitors | 3 | 17.0 |
Drug Administration Schedule | 31 | 3.0 |
Estradiol/*blood | 27 | 17.0 |
Fetal Blood/chemistry | 2 | 3.0 |
Postpartum Period/blood | 6 | 30.0 |
Amenorrhea/*etiology | 6 | 66.0 |
Bromocriptine/pharmacology/*therapeutic use | 4 | 80.0 |
Galactorrhea/*etiology | 4 | 100.0 |
Pituitary Neoplasms/*complications/surgery | 2 | 66.0 |
Cycloheximide/pharmacology | 4 | 0.0 |
Estradiol/*pharmacology | 8 | 3.0 |
Medroxyprogesterone 17-Acetate/pharmacology | 4 | 12.0 |
Mifepristone/pharmacology | 2 | 2.0 |
Progesterone/*pharmacology | 7 | 8.0 |
Circadian Rhythm/physiology | 6 | 10.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Vision Disorders/etiology | 4 | 23.0 |
DNA/analysis/genetics | 4 | 2.0 |
Hypothyroidism/genetics | 2 | 40.0 |
Dopamine/pharmacology | 19 | 51.0 |
Growth Substances/*pharmacology | 5 | 1.0 |
Antipsychotic Agents/*adverse effects | 4 | 21.0 |
Haloperidol/*adverse effects | 2 | 66.0 |
Hyperprolactinemia/*diagnosis | 5 | 100.0 |
Proteins/analysis | 2 | 1.0 |
Species Specificity | 19 | 0.0 |
Binding, Competitive | 14 | 0.0 |
Dopamine/metabolism | 9 | 7.0 |
Norepinephrine/metabolism | 4 | 8.0 |
Plasmids | 3 | 0.0 |
Hyperprolactinemia/blood/*drug therapy/physiopathology | 4 | 100.0 |
Prolactin/*blood/metabolism | 7 | 100.0 |
Stereoisomerism | 3 | 0.0 |
Pituitary Gland/*physiology | 9 | 37.0 |
Dopamine/blood | 3 | 12.0 |
Evaluation Studies | 3 | 0.0 |
Acromegaly/*complications | 2 | 40.0 |
Hormones/therapeutic use | 3 | 17.0 |
Gonadorelin/pharmacology | 23 | 51.0 |
Luteinizing Hormone/blood/*secretion | 22 | 84.0 |
Follicle Stimulating Hormone/pharmacology | 7 | 12.0 |
Prolactin/analysis/*metabolism | 2 | 100.0 |
Depressive Disorder/*blood/*therapy | 2 | 100.0 |
*Electroconvulsive Therapy | 11 | 64.0 |
Prolactin/blood/*cerebrospinal fluid | 5 | 100.0 |
Pituitary Gland, Anterior/pathology | 2 | 50.0 |
Ergolines/*pharmacology | 17 | 94.0 |
Growth Hormone/genetics/*physiology | 2 | 50.0 |
Organ Culture Techniques | 8 | 2.0 |
Linear Models | 2 | 0.0 |
Endocrine System Diseases/*chemically induced | 2 | 100.0 |
Lipids/blood | 2 | 0.0 |
Sulpiride/*adverse effects | 3 | 100.0 |
Body Height | 7 | 4.0 |
Corticotropin/*blood | 13 | 20.0 |
Benzamides/*diagnostic use | 3 | 100.0 |
Iodine Radioisotopes/*diagnostic use | 2 | 3.0 |
Pyrrolidines/*diagnostic use | 2 | 100.0 |
Tomography, Emission-Computed, Single-Photon | 3 | 5.0 |
Gestational Age | 17 | 1.0 |
Somatostatin/pharmacology | 10 | 20.0 |
Secretory Rate/physiology | 2 | 25.0 |
Half-Life | 6 | 1.0 |
Pituitary Gland, Anterior/*secretion | 10 | 66.0 |
Somatotropin-Releasing Hormone/*therapeutic use | 3 | 27.0 |
Triiodothyronine, Reverse/blood | 3 | 10.0 |
*Uterine Contraction | 2 | 66.0 |
Amniotic Fluid/*chemistry | 3 | 6.0 |
*Breast Feeding | 8 | 12.0 |
Fetal Blood | 3 | 2.0 |
Infant, Newborn/*blood | 2 | 4.0 |
Dopamine Agonists/administration & dosage/*therapeutic use | 3 | 100.0 |
Pituitary Neoplasms/complications/*drug therapy | 2 | 100.0 |
*Pregnancy Outcome | 2 | 3.0 |
Acromegaly/*drug therapy | 7 | 38.0 |
Adenoma/drug therapy | 6 | 100.0 |
Testis/*metabolism | 4 | 4.0 |
Transcription, Genetic/*drug effects | 3 | 0.0 |
Pituitary Gland/metabolism | 14 | 25.0 |
Chorionic Gonadotropin/therapeutic use | 9 | 30.0 |
Menotropins/therapeutic use | 4 | 28.0 |
Pituitary Neoplasms/complications/diagnosis/*drug therapy | 3 | 100.0 |
Prolactinoma/complications/diagnosis/*drug therapy | 2 | 100.0 |
Pituitary Function Tests | 20 | 64.0 |
Pituitary Hormones/blood | 2 | 28.0 |
Perimetry | 2 | 7.0 |
Pituitary Neoplasms/*drug therapy/pathology/physiopathology | 2 | 100.0 |
Prolactinoma/*drug therapy/pathology/physiopathology | 2 | 100.0 |
Cytoplasm/chemistry | 2 | 1.0 |
Cytoplasmic Granules/ultrastructure | 3 | 8.0 |
Growth Hormone/*analysis | 6 | 85.0 |
Hormones/*secretion | 6 | 50.0 |
Leuprolide | 3 | 30.0 |
Melatonin/secretion | 3 | 50.0 |
*Sex Characteristics | 4 | 2.0 |
Testosterone/*pharmacology | 5 | 16.0 |
COS Cells | 2 | 0.0 |
Cell Differentiation | 5 | 0.0 |
Receptors, Prolactin/biosynthesis/*physiology | 2 | 100.0 |
Recombinant Proteins/metabolism | 4 | 0.0 |
Insulin-Like Growth Factor I/*secretion | 2 | 66.0 |
Glucagon/diagnostic use | 2 | 16.0 |
Water Deprivation | 3 | 18.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 2 | 0.0 |
*Proto-Oncogenes | 3 | 0.0 |
Zinc/*metabolism | 2 | 3.0 |
Prolactin/biosynthesis | 9 | 64.0 |
Mitogens/pharmacology | 3 | 1.0 |
*Adaptor Proteins, Signal Transducing | 2 | 0.0 |
Proteins/metabolism | 2 | 0.0 |
Receptors, Prolactin/genetics/metabolism | 4 | 80.0 |
Depressive Disorder/blood/*therapy | 2 | 66.0 |
Dominance, Cerebral/physiology | 2 | 7.0 |
Electroencephalography | 5 | 2.0 |
*Bone Marrow Cells | 2 | 0.0 |
Follicle Stimulating Hormone/biosynthesis | 2 | 100.0 |
Pituitary-Adrenal System/*physiology | 2 | 14.0 |
Acromegaly/*blood | 12 | 60.0 |
*Interleukin-6 | 2 | 0.0 |
Recombinant Fusion Proteins/biosynthesis | 2 | 0.0 |
Isoelectric Focusing | 3 | 0.0 |
Chorionic Gonadotropin/pharmacology | 18 | 14.0 |
Organ Size/drug effects | 5 | 5.0 |
Vasopressins/deficiency | 2 | 100.0 |
Infertility, Male/*blood/drug therapy | 2 | 100.0 |
Semen/cytology | 2 | 40.0 |
Sperm Count | 11 | 18.0 |
Amenorrhea/*metabolism | 3 | 100.0 |
Dopamine Antagonists/*pharmacology | 3 | 30.0 |
Protirelin/*pharmacology | 45 | 63.0 |
Acromegaly/*drug therapy/physiopathology | 3 | 75.0 |
Thyroid Function Tests | 7 | 8.0 |
Skin/pathology | 2 | 0.0 |
Receptors, Estrogen/*genetics | 2 | 2.0 |
*Variation (Genetics) | 2 | 0.0 |
Domperidone/*diagnostic use | 6 | 100.0 |
*Magnetic Resonance Imaging | 5 | 3.0 |
Prolactinoma/complications/diagnosis | 2 | 100.0 |
Pituitary Neoplasms/blood/*drug therapy/physiopathology | 2 | 100.0 |
Prolactinoma/blood/*drug therapy/physiopathology | 2 | 100.0 |
Blood Pressure/physiology | 3 | 1.0 |
Heart Rate/physiology | 3 | 3.0 |
Norepinephrine/*blood | 5 | 8.0 |
Incidence | 5 | 0.0 |
Japan/epidemiology | 2 | 0.0 |
Fenfluramine/*diagnostic use | 2 | 100.0 |
Body Composition | 3 | 1.0 |
Body Weight | 24 | 3.0 |
Fasting | 6 | 1.0 |
Reproduction/*physiology | 3 | 11.0 |
Menstruation Disturbances/etiology | 4 | 50.0 |
Growth Hormone/secretion | 41 | 48.0 |
Immune Sera | 3 | 1.0 |
Pituitary Neoplasms/*genetics | 2 | 8.0 |
Signal Transduction/*genetics | 2 | 1.0 |
Arthritis, Rheumatoid/blood | 2 | 7.0 |
Lupus Erythematosus, Systemic/*blood/complications | 2 | 20.0 |
Dopamine beta-Hydroxylase/blood | 2 | 5.0 |
Monoamine Oxidase/blood | 2 | 18.0 |
Prolactin/*biosynthesis | 17 | 94.0 |
Blood Pressure/*drug effects | 5 | 3.0 |
Metabolic Clearance Rate | 4 | 1.0 |
Pulse/drug effects | 4 | 21.0 |
Arginine/diagnostic use | 7 | 26.0 |
Dopamine Antagonists | 15 | 78.0 |
Follicular Phase | 18 | 38.0 |
Prolactin/*antagonists & inhibitors/secretion | 2 | 100.0 |
Acromegaly/*etiology | 2 | 28.0 |
Bromocriptine/*adverse effects | 2 | 100.0 |
Progesterone/secretion | 4 | 30.0 |
Affect/*drug effects | 3 | 33.0 |
Body Temperature/drug effects | 2 | 5.0 |
Drug Interactions | 25 | 2.0 |
Dopamine beta-Hydroxylase/*drug effects | 2 | 100.0 |
Monoamine Oxidase/*drug effects | 2 | 100.0 |
*Occupational Exposure | 3 | 2.0 |
Neurotoxins/*toxicity | 2 | 22.0 |
Depressive Disorder/blood/*diagnosis | 3 | 100.0 |
Secretory Rate/drug effects | 19 | 22.0 |
*Pregnancy Complications, Neoplastic | 2 | 25.0 |
Alkaline Phosphatase/blood | 5 | 3.0 |
Lactation/blood | 2 | 66.0 |
Parathyroid Hormone-Related Protein | 2 | 2.0 |
Body Temperature | 10 | 10.0 |
Darkness | 2 | 6.0 |
Light | 2 | 0.0 |
Melatonin/blood/secretion | 2 | 100.0 |
Probability | 2 | 0.0 |
Wakefulness/physiology | 2 | 13.0 |
Androgens/*secretion | 3 | 50.0 |
Menstrual Cycle/*drug effects | 6 | 75.0 |
Polycystic Ovary Syndrome/blood/*drug therapy | 7 | 63.0 |
Gene Expression Regulation, Neoplastic | 4 | 0.0 |
Blood Glucose/metabolism | 13 | 1.0 |
Growth Hormone/blood/secretion | 5 | 50.0 |
Hydrocortisone/blood/secretion | 2 | 25.0 |
Hypothalamus/drug effects/secretion | 2 | 33.0 |
Pituitary Gland/*drug effects/secretion | 2 | 22.0 |
Protirelin/*therapeutic use | 4 | 66.0 |
Thyrotropin/blood/secretion | 7 | 77.0 |
Corticotropin-Releasing Hormone/pharmacology | 8 | 22.0 |
Pituitary-Adrenal System/*physiopathology | 3 | 12.0 |
Neuropeptides/*pharmacology | 3 | 5.0 |
Pituitary Hormones, Anterior/*secretion | 15 | 83.0 |
Vasoactive Intestinal Peptide/*pharmacology | 7 | 7.0 |
Dehydroepiandrosterone/analogs & derivatives/blood | 14 | 22.0 |
Menotropins/*therapeutic use | 2 | 40.0 |
Testosterone/*therapeutic use | 2 | 25.0 |
Hypophysectomy | 16 | 30.0 |
Liver/*metabolism | 6 | 1.0 |
DNA/genetics | 2 | 0.0 |
Molecular Probes/genetics | 3 | 3.0 |
Fertilization in Vitro/*methods | 3 | 11.0 |
Menotropins/pharmacology | 5 | 38.0 |
Ovary/drug effects/*physiology | 3 | 42.0 |
Ovulation Induction/*methods | 6 | 54.0 |
Injections, Intramuscular | 20 | 12.0 |
Pituitary Neoplasms/*drug therapy/radiography | 3 | 100.0 |
Prolactinoma/*drug therapy/radiography | 3 | 100.0 |
Cushing Syndrome/*metabolism | 3 | 27.0 |
*Petrosal Sinus Sampling | 2 | 28.0 |
beta-Endorphin/blood | 6 | 17.0 |
Cell Membrane/metabolism | 12 | 0.0 |
DNA Probes | 4 | 0.0 |
Thyroid Hormones/*blood | 10 | 16.0 |
Visual Fields/drug effects | 8 | 80.0 |
Bucladesine/pharmacology | 5 | 2.0 |
Decidua/metabolism | 2 | 7.0 |
Dinoprostone/pharmacology | 2 | 2.0 |
Adenoma/metabolism/pathology/*secretion | 2 | 66.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Pituitary Neoplasms/metabolism/pathology/*secretion | 2 | 66.0 |
Hyperprolactinemia/blood/*etiology | 3 | 100.0 |
Survival Analysis | 2 | 0.0 |
Culture Media | 10 | 1.0 |
Progesterone/pharmacology | 9 | 7.0 |
8-Bromo Cyclic Adenosine Monophosphate/pharmacology | 2 | 2.0 |
Cell Line, Transformed | 2 | 0.0 |
Endometrium/*cytology | 2 | 10.0 |
Pituitary Gland, Anterior/*physiopathology | 8 | 72.0 |
Follicular Phase/physiology | 3 | 21.0 |
Luteal Phase/physiology | 5 | 23.0 |
Sleep Deprivation/*physiology | 4 | 44.0 |
Chickens | 6 | 0.0 |
Growth Hormone/*metabolism | 10 | 19.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Radioligand Assay | 17 | 3.0 |
Swine | 7 | 0.0 |
Hypothalamus/physiopathology | 7 | 43.0 |
Insulin/diagnostic use | 20 | 42.0 |
Domperidone/diagnostic use/*pharmacology | 2 | 100.0 |
Empty Sella Syndrome/*blood | 2 | 66.0 |
Hyperprolactinemia/blood | 8 | 88.0 |
Melatonin/*blood | 4 | 40.0 |
Testis/pathology | 2 | 4.0 |
Cyclic AMP/metabolism | 2 | 0.0 |
Insulin/*secretion | 2 | 2.0 |
Phenols/pharmacology | 2 | 7.0 |
Prolactin/metabolism/*pharmacology | 2 | 66.0 |
Adenoma/diagnosis/*secretion | 3 | 100.0 |
Arginine/*pharmacology | 5 | 16.0 |
Bromocriptine/adverse effects/*pharmacology | 3 | 100.0 |
Dexamethasone/pharmacology | 11 | 2.0 |
Luciferases/biosynthesis | 2 | 2.0 |
Ovary/*metabolism | 2 | 3.0 |
Luteal Phase | 25 | 38.0 |
Sleep | 13 | 44.0 |
Urine/physiology | 2 | 20.0 |
Wakefulness | 5 | 31.0 |
Premedication | 3 | 15.0 |
Protirelin/*administration & dosage | 8 | 88.0 |
Antibodies, Anticardiolipin/blood | 2 | 7.0 |
Galactorrhea/*blood | 9 | 100.0 |
Testosterone/secretion | 3 | 60.0 |
False Negative Reactions | 2 | 1.0 |
*Immunoradiometric Assay | 2 | 33.0 |
Pituitary Neoplasms/blood/*diagnosis | 2 | 50.0 |
Prolactinoma/blood/*diagnosis | 2 | 100.0 |
DNA, Complementary/genetics | 3 | 0.0 |
Endometrium/*cytology/metabolism | 2 | 22.0 |
Cloning, Molecular | 7 | 0.0 |
Gene Library | 2 | 0.0 |
Growth Hormone/*genetics | 6 | 16.0 |
Brain/*physiology | 2 | 1.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
Genotype | 2 | 0.0 |
Heterozygote | 2 | 0.0 |
Autoradiography | 6 | 1.0 |
Amenorrhea/*blood | 14 | 77.0 |
Lactation/*blood | 7 | 70.0 |
Postpartum Period/*blood | 7 | 43.0 |
Prolactin/genetics/*secretion | 2 | 100.0 |
Hormones/*metabolism | 2 | 8.0 |
Pindolol/*pharmacology | 3 | 60.0 |
Prolactin/*biosynthesis/genetics | 2 | 66.0 |
Growth Hormone/genetics/*secretion | 2 | 50.0 |
Pituitary Neoplasms/metabolism | 6 | 37.0 |
Cell Survival | 5 | 0.0 |
Down-Regulation | 3 | 0.0 |
Transcription Factors/*metabolism | 4 | 0.0 |
Carbidopa/pharmacology | 4 | 80.0 |
Hyperprolactinemia/blood/*chemically induced | 2 | 100.0 |
Levodopa/pharmacology | 11 | 40.0 |
Cyclosporine/pharmacology | 2 | 0.0 |
Immune System/*physiology | 2 | 3.0 |
T-Lymphocytes/immunology | 2 | 0.0 |
Carrier Proteins/*blood | 3 | 1.0 |
Infertility, Male/*metabolism | 2 | 9.0 |
Oligospermia/metabolism | 3 | 27.0 |
Neoplasm Invasiveness | 3 | 0.0 |
Transcription, Genetic/*physiology | 2 | 1.0 |
RNA, Messenger/*metabolism | 4 | 0.0 |
Diabetes Mellitus, Type 1/*blood | 4 | 2.0 |
Gonadorelin/administration & dosage | 3 | 60.0 |
Luteinizing Hormone/*analysis | 2 | 100.0 |
Protirelin/administration & dosage | 3 | 37.0 |
Octreotide/*pharmacology | 2 | 9.0 |
Insulin-Like Growth Factor I/pharmacology/*physiology | 2 | 16.0 |
Prolactin/pharmacology/physiology | 2 | 100.0 |
Estrogens/*physiology | 3 | 7.0 |
Hypopituitarism/*metabolism | 2 | 100.0 |
Phenothiazines/pharmacology | 2 | 28.0 |
Pituitary Gland/physiopathology | 9 | 75.0 |
Antineoplastic Agents/*pharmacology | 3 | 0.0 |
Melatonin/*pharmacology | 2 | 18.0 |
Receptors, Prolactin/drug effects | 2 | 50.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
Sperm Motility | 6 | 12.0 |
Breast Neoplasms/pathology | 2 | 1.0 |
Receptors, Estrogen/*metabolism | 2 | 0.0 |
Decidua/cytology/*metabolism | 2 | 28.0 |
Naloxone/*diagnostic use | 6 | 85.0 |
Ovulation | 15 | 29.0 |
Pituitary Gland/drug effects/secretion | 8 | 66.0 |
Chorionic Gonadotropin/*pharmacology | 8 | 14.0 |
Gonadorelin/agonists | 2 | 11.0 |
RNA, Messenger/analysis/genetics/metabolism | 2 | 5.0 |
Lymphoma/pathology | 2 | 7.0 |
N-Acetylneuraminic Acid | 2 | 5.0 |
Lymphocytes/*metabolism | 4 | 2.0 |
Receptors, Prolactin/drug effects/*metabolism | 3 | 100.0 |
Insulin/*pharmacology | 8 | 3.0 |
*Lymphocyte Activation | 2 | 0.0 |
Hypothyroidism/drug therapy/*physiopathology | 2 | 100.0 |
Protirelin/administration & dosage/pharmacology | 3 | 75.0 |
Dehydroepiandrosterone/*analogs & derivatives/blood | 2 | 11.0 |
Adenoma/*blood | 4 | 66.0 |
Calcium/*blood | 3 | 3.0 |
Hyperprolactinemia/etiology/*physiopathology | 2 | 100.0 |
Parathyroid Hormone/*blood | 5 | 5.0 |
Phosphates/*blood | 2 | 22.0 |
Glycoproteins/*blood | 2 | 2.0 |
*Light | 2 | 5.0 |
Sexual Maturation | 3 | 12.0 |
Stress/*blood | 3 | 25.0 |
Receptors, Somatotropin/*metabolism | 2 | 10.0 |
Cushing Syndrome/*etiology | 3 | 25.0 |
Corticotropin/*secretion | 6 | 13.0 |
Gonadotropins, Pituitary/*secretion | 8 | 72.0 |
Sleep, REM | 2 | 33.0 |
Domperidone/pharmacology | 10 | 100.0 |
Interleukin-1/administration & dosage/*pharmacology | 2 | 16.0 |
Receptors, Dopamine/physiology | 5 | 71.0 |
Amenorrhea | 2 | 40.0 |
Menopause | 18 | 8.0 |
Hyperprolactinemia/*chemically induced | 3 | 75.0 |
Triptorelin/*adverse effects | 2 | 100.0 |
Prolactin/*analogs & derivatives/*blood | 3 | 100.0 |
Stress/blood | 2 | 18.0 |
Surgical Procedures, Operative | 2 | 14.0 |
Glycoprotein Hormones, alpha Subunit/analysis | 2 | 50.0 |
In Situ Hybridization/methods | 2 | 1.0 |
Prolactin/analysis/*biosynthesis | 2 | 100.0 |
Endometrium/pathology | 4 | 30.0 |
*Sperm Motility | 3 | 12.0 |
Pituitary Neoplasms/blood/*drug therapy | 4 | 66.0 |
Prolactinoma/blood/*drug therapy | 4 | 100.0 |
Pituitary Gland, Anterior/*metabolism | 2 | 14.0 |
Amenorrhea/*physiopathology | 3 | 60.0 |
Follicle Stimulating Hormone/blood/secretion | 7 | 50.0 |
Gonadorelin/*therapeutic use | 2 | 66.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Cercopithecus aethiops | 2 | 0.0 |
Columbidae | 3 | 20.0 |
Kidney | 2 | 0.0 |
RNA, Messenger/analysis/biosynthesis | 2 | 0.0 |
Recombinant Proteins/biosynthesis/metabolism | 2 | 1.0 |
Hypertension/physiopathology | 2 | 9.0 |
Metoclopramide/pharmacology | 31 | 93.0 |
Renin/blood | 15 | 4.0 |
*Embryo Transfer | 5 | 20.0 |
Feedback | 8 | 4.0 |
Immunochemistry | 3 | 1.0 |
Infant, Premature | 2 | 1.0 |
Bromocriptine/diagnostic use | 11 | 100.0 |
Dopamine/*pharmacology | 20 | 71.0 |
Adenoma/blood/drug therapy/*secretion | 3 | 100.0 |
Bromocriptine/*administration & dosage/therapeutic use | 6 | 100.0 |
Pituitary Neoplasms/blood/drug therapy/*secretion | 2 | 100.0 |
Thyroid Hormones/therapeutic use | 2 | 22.0 |
Infusion Pumps | 2 | 7.0 |
Prolactin/physiology | 3 | 37.0 |
Aminoquinolines/administration & dosage/*therapeutic use | 3 | 100.0 |
Receptors, Prolactin/*analysis | 4 | 50.0 |
Pituitary Neoplasms/drug therapy/radiography | 2 | 100.0 |
Clone Cells | 2 | 0.0 |
*Gene Expression Regulation/drug effects | 2 | 1.0 |
Phosphotyrosine | 2 | 0.0 |
Zinc/*pharmacology | 3 | 9.0 |
Galactorrhea/*chemically induced | 3 | 100.0 |
Pituitary Gland/drug effects/metabolism | 2 | 28.0 |
Macaca mulatta | 9 | 2.0 |
Carps | 2 | 25.0 |
DNA-Binding Proteins/*physiology | 2 | 0.0 |
Hela Cells | 3 | 0.0 |
Transcription Factors/*physiology | 2 | 0.0 |
Receptors, LHRH/*analysis | 3 | 60.0 |
Hypothalamo-Hypophyseal System/*drug effects | 4 | 21.0 |
Ovary/*drug effects | 3 | 37.0 |
Estradiol/blood/metabolism | 2 | 20.0 |
Menotropins/*adverse effects/therapeutic use | 2 | 100.0 |
Ovulation Induction | 7 | 17.0 |
Genes, Structural | 2 | 0.0 |
Acromegaly/*metabolism | 7 | 46.0 |
Corpus Luteum/*metabolism | 3 | 16.0 |
Follicle Stimulating Hormone/metabolism | 5 | 20.0 |
Hyperprolactinemia/blood/*drug therapy | 10 | 100.0 |
Domperidone/*pharmacology | 8 | 88.0 |
Reagent Kits, Diagnostic | 2 | 1.0 |
Receptors, Prolactin/*isolation & purification/metabolism | 2 | 100.0 |
Dopamine/*blood | 3 | 42.0 |
Adenoma/*metabolism/pathology | 3 | 8.0 |
Pituitary Neoplasms/*metabolism/pathology | 4 | 30.0 |
Hypothalamo-Hypophyseal System/*secretion | 2 | 66.0 |
Levodopa/diagnostic use | 17 | 65.0 |
Pituitary-Adrenal System/*secretion | 2 | 66.0 |
Argipressin/pharmacology | 3 | 6.0 |
Blood-Brain Barrier | 4 | 6.0 |
Corticotropin-Releasing Hormone/*pharmacology | 2 | 8.0 |
Hypothalamo-Hypophyseal System/physiology | 3 | 10.0 |
Sulpiride/pharmacology | 15 | 88.0 |
Lymphotoxin/pharmacology | 2 | 9.0 |
Stromal Cells/*metabolism | 2 | 5.0 |
Climacteric/*drug effects | 5 | 50.0 |
Estrogens, Conjugated (USP)/administration & dosage | 2 | 28.0 |
Pituitary Gland/drug effects | 7 | 50.0 |
Prolactin/*antagonists & inhibitors/blood | 6 | 100.0 |
Prolactin/blood/*urine | 2 | 100.0 |
Bromocriptine/administration & dosage/adverse effects/*therapeutic use | 4 | 100.0 |
Immunologic Techniques | 2 | 0.0 |
*Lactation | 18 | 62.0 |
Hypothalamus/*metabolism | 2 | 6.0 |
Verapamil/*pharmacology | 4 | 12.0 |
Epidermal Growth Factor/pharmacology | 6 | 0.0 |
Insulin-Like Growth Factor Binding Protein 1 | 2 | 9.0 |
Lactation | 11 | 21.0 |
*Reproduction | 4 | 20.0 |
Prolactin/*blood/physiology | 9 | 100.0 |
Hyperthyroidism/*blood | 4 | 20.0 |
Adenoma/complications | 8 | 47.0 |
Hypertension/etiology | 2 | 4.0 |
Pituitary Neoplasms/complications | 9 | 64.0 |
Cushing Syndrome/*physiopathology | 2 | 50.0 |
Gonadorelin/*diagnostic use | 14 | 82.0 |
Obesity/*physiopathology | 7 | 12.0 |
Galactorrhea/blood | 13 | 92.0 |
Adrenal Glands/physiopathology | 2 | 25.0 |
Ovary/physiopathology | 3 | 18.0 |
Pituitary Neoplasms/physiopathology/*surgery | 2 | 100.0 |
Biological Transport | 2 | 0.0 |
Insulin/pharmacology | 17 | 6.0 |
Pituitary Neoplasms/metabolism/*pathology | 2 | 50.0 |
Serine | 2 | 2.0 |
Alopecia/blood/*etiology | 2 | 100.0 |
Pituitary Neoplasms/blood/pathology/*secretion | 2 | 100.0 |
Naloxone/*pharmacology | 12 | 42.0 |
Valproic Acid/*pharmacology | 4 | 21.0 |
gamma-Aminobutyric Acid/*physiology | 4 | 26.0 |
Receptors, Progesterone/*analysis | 3 | 1.0 |
Chloramphenicol O-Acetyltransferase/genetics | 2 | 0.0 |
Hypothalamo-Hypophyseal System/physiopathology | 8 | 22.0 |
Neuropeptides/physiology | 2 | 7.0 |
Decidua/drug effects/*physiology | 4 | 66.0 |
Endometrium/cytology/drug effects/*physiology | 3 | 60.0 |
Restriction Mapping | 3 | 0.0 |
Ovary/*physiology | 12 | 32.0 |
Growth Hormone/*deficiency | 7 | 24.0 |
Hydrocortisone/therapeutic use | 2 | 11.0 |
Estradiol/metabolism | 6 | 6.0 |
False Positive Reactions | 2 | 0.0 |
Hyperprolactinemia/diagnosis/*etiology | 2 | 100.0 |
Immunoglobulin G/*blood | 3 | 4.0 |
*Physical Endurance | 2 | 4.0 |
Receptors, Serotonin/drug effects/metabolism | 2 | 66.0 |
*Radioimmunoassay | 3 | 7.0 |
Breast Neoplasms/*blood/drug therapy/pathology | 2 | 50.0 |
Tamoxifen/*therapeutic use | 4 | 5.0 |
Prolactin/immunology/*physiology | 2 | 100.0 |
Follicular Fluid/*chemistry | 3 | 12.0 |
Testosterone/analysis | 2 | 18.0 |
Vasoactive Intestinal Peptide/pharmacology | 3 | 3.0 |
Protirelin/diagnostic use/pharmacology | 2 | 66.0 |
Thyroxine/*therapeutic use | 2 | 11.0 |
Prolactin/analysis/*genetics | 3 | 100.0 |
Mice, Inbred C3H | 3 | 0.0 |
Prolactin/blood/pharmacology | 3 | 60.0 |
Epithelial Cells | 3 | 0.0 |
Gene Expression/*drug effects | 2 | 0.0 |
Growth Hormone/biosynthesis | 2 | 20.0 |
Pituitary Gland/cytology/drug effects/*metabolism | 2 | 40.0 |
Pituitary Hormones/*biosynthesis | 2 | 50.0 |
Thymidine/metabolism | 2 | 0.0 |
Epilepsy, Temporal Lobe/*blood | 2 | 100.0 |
Sleep Stages/physiology | 4 | 23.0 |
Insulin-Like Growth Factor I/*analysis | 2 | 3.0 |
*Smoking | 4 | 4.0 |
*Abortion, Induced | 2 | 9.0 |
Cell Division/drug effects/physiology | 3 | 1.0 |
Chromatography, High Pressure Liquid | 9 | 0.0 |
Interleukins/pharmacology | 2 | 2.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 2 | 0.0 |
Brain Chemistry/*physiology | 2 | 3.0 |
Endorphins/*physiology | 7 | 43.0 |
Ethanol/*pharmacology | 4 | 3.0 |
Lactation/drug effects | 4 | 80.0 |
Naloxone/pharmacology | 11 | 23.0 |
Physical Stimulation | 5 | 11.0 |
Pituitary Gland, Anterior/drug effects/secretion | 3 | 42.0 |
Hyperprolactinemia/blood/drug therapy/*etiology | 2 | 100.0 |
Carcinoembryonic Antigen/blood | 2 | 3.0 |
Somatotropin-Releasing Hormone/blood | 2 | 28.0 |
Aminoquinolines/*pharmacology | 2 | 16.0 |
Dopamine Agents/*pharmacology | 5 | 55.0 |
Homovanillic Acid/*blood | 2 | 25.0 |
Schizophrenia/*blood/*drug therapy | 2 | 50.0 |
Dinoprostone/*pharmacology | 2 | 3.0 |
Dopamine/administration & dosage/*pharmacology | 4 | 100.0 |
Growth Hormone/blood/*secretion | 31 | 33.0 |
Infant, Newborn/*physiology | 3 | 18.0 |
Luteinizing Hormone/*blood/secretion | 3 | 75.0 |
Menstrual Cycle/*blood | 3 | 21.0 |
Menstruation Disturbances/*blood | 5 | 83.0 |
Adenoma, Chromophobe/secretion | 3 | 100.0 |
Pituitary Gland, Anterior/physiopathology | 7 | 87.0 |
Placenta/*metabolism | 2 | 1.0 |
Placental Lactogen/metabolism | 2 | 11.0 |
Protein Biosynthesis | 7 | 0.0 |
Reticulocytes/metabolism | 2 | 2.0 |
Galactorrhea/blood/complications | 2 | 100.0 |
DNA, Neoplasm/biosynthesis | 2 | 1.0 |
Gonadotropins/*blood | 10 | 41.0 |
*Ovariectomy | 4 | 9.0 |
Ergolines/*administration & dosage/adverse effects | 2 | 100.0 |
Dopamine/physiology | 13 | 24.0 |
Decidua/drug effects/*secretion | 2 | 100.0 |
Epithelium/metabolism | 2 | 0.0 |
Galanin | 4 | 10.0 |
Peptides/*pharmacology | 3 | 1.0 |
Growth Hormone/*blood/metabolism | 2 | 50.0 |
Metoclopramide/administration & dosage/*pharmacology | 6 | 100.0 |
Clomiphene/*therapeutic use | 4 | 57.0 |
Dwarfism/*genetics | 2 | 8.0 |
Pituitary Gland/secretion/transplantation | 2 | 100.0 |
Cats | 2 | 0.0 |
Cross Reactions | 2 | 0.0 |
Horses | 2 | 1.0 |
Aldosterone/blood | 8 | 4.0 |
*Delivery, Obstetric | 3 | 17.0 |
Endometrium/cytology/drug effects/*metabolism | 2 | 15.0 |
Tissue Extracts/*pharmacology | 2 | 8.0 |
Growth Hormone/*blood/secretion | 3 | 27.0 |
Prolactin/*biosynthesis/blood | 2 | 100.0 |
Diabetes Complications | 3 | 2.0 |
Prolactin/*blood/chemistry | 3 | 100.0 |
Aging/*physiology | 2 | 0.0 |
Gonadotropins/*secretion | 4 | 66.0 |
Testosterone/pharmacology | 4 | 6.0 |
Menstrual Cycle/drug effects | 6 | 35.0 |
Prolactin/blood/*drug effects | 2 | 66.0 |
Dopamine Agents/adverse effects/*therapeutic use | 5 | 100.0 |
Impotence/drug therapy | 3 | 60.0 |
Menstruation/drug effects | 8 | 61.0 |
Dopamine Agents/administration & dosage/*therapeutic use | 3 | 100.0 |
Pituitary Neoplasms/*drug therapy/physiopathology | 2 | 100.0 |
Renin-Angiotensin System/*drug effects | 2 | 1.0 |
Brain Chemistry | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/genetics | 2 | 1.0 |
Drug Implants | 5 | 12.0 |
Pancreatic Polypeptide/blood | 2 | 3.0 |
Somatostatin/blood | 4 | 16.0 |
Cell Transformation, Neoplastic | 3 | 0.0 |
Pituitary Gland/*metabolism/pathology | 2 | 100.0 |
Luteal Phase/blood | 2 | 33.0 |
Growth Hormone/blood/*genetics | 2 | 50.0 |
Prolactin/blood/*genetics | 2 | 100.0 |
Arginine/pharmacology | 3 | 10.0 |
Placental Lactogen/*blood | 6 | 19.0 |
Corticotropin-Releasing Hormone/diagnostic use | 3 | 25.0 |
Hydrocortisone/blood/*secretion | 2 | 20.0 |
Empty Sella Syndrome/*physiopathology | 2 | 100.0 |
Hypothalamo-Hypophyseal System/drug effects/physiology | 3 | 33.0 |
Corticotropin/*metabolism | 3 | 21.0 |
Clozapine/*pharmacology/therapeutic use | 2 | 40.0 |
Hypothalamo-Hypophyseal System/metabolism | 2 | 22.0 |
Immunosorbent Techniques | 2 | 0.0 |
Lymphoma/metabolism | 2 | 9.0 |
Fertilization in Vitro | 9 | 6.0 |
Ovarian Follicle/metabolism | 2 | 13.0 |
Pregnancy/metabolism | 2 | 25.0 |
Nucleic Acid Hybridization | 11 | 0.0 |
RNA, Messenger/analysis/genetics | 3 | 0.0 |
Calcium Channels/drug effects/physiology | 2 | 33.0 |
Hypothyroidism/complications | 3 | 37.0 |
Japan | 2 | 0.0 |
Bromocriptine/administration & dosage/*pharmacology | 2 | 100.0 |
Bromocriptine/administration & dosage/*adverse effects | 2 | 100.0 |
Adenoma/*complications | 2 | 66.0 |
Fibrous Dysplasia, Polyostotic/*complications | 2 | 100.0 |
Growth Hormone/blood/drug effects | 2 | 100.0 |
Pituitary Neoplasms/*complications | 2 | 40.0 |
Arousal/*physiology | 2 | 6.0 |
Catecholamines/urine | 2 | 16.0 |
Neuropsychological Tests | 4 | 1.0 |
Reaction Time/physiology | 2 | 2.0 |
Hospitalization | 2 | 1.0 |
Hospitals, Psychiatric | 2 | 28.0 |
Schizophrenic Psychology | 5 | 14.0 |
Estrone/blood | 13 | 16.0 |
Fructose/metabolism | 2 | 22.0 |
Sperm Motility/drug effects | 4 | 28.0 |
Spermatozoa/drug effects/*physiology | 2 | 20.0 |
Pituitary Neoplasms/*drug therapy/secretion | 7 | 100.0 |
Pregnancy/blood | 2 | 15.0 |
Sella Turcica/pathology | 3 | 100.0 |
Nausea/chemically induced | 2 | 6.0 |
Pituitary Gland/physiology | 8 | 30.0 |
Liver/metabolism | 3 | 0.0 |
Tumor Cells, Cultured/metabolism | 2 | 1.0 |
5-Hydroxytryptophan/*pharmacology | 2 | 100.0 |
Receptors, Serotonin/drug effects/physiology | 2 | 40.0 |
Dopamine/diagnostic use | 4 | 66.0 |
Sulpiride/diagnostic use | 8 | 88.0 |
Antipsychotic Agents/administration & dosage/*therapeutic use | 2 | 66.0 |
17-alpha-Hydroxyprogesterone | 7 | 15.0 |
Estradiol/secretion | 3 | 37.0 |
Hydroxyprogesterones/blood | 11 | 22.0 |
Postpartum Period/blood/*physiology | 2 | 100.0 |
Prolactin/blood/*physiology | 7 | 100.0 |
Hypothalamus/drug effects | 7 | 53.0 |
Lipids/metabolism | 3 | 0.0 |
Pituitary Hormone-Releasing Hormones/pharmacology | 10 | 83.0 |
Macaca fascicularis | 2 | 0.0 |
Pregnancy/*metabolism | 3 | 5.0 |
Hypothalamo-Hypophyseal System/*drug effects/physiopathology | 3 | 60.0 |
Luteinizing Hormone/blood/secretion | 8 | 44.0 |
Testosterone/blood/secretion | 2 | 66.0 |
Thyroxine/blood/secretion | 3 | 100.0 |
Triiodothyronine/blood/secretion | 3 | 100.0 |
Bromocriptine/*administration & dosage/adverse effects | 2 | 100.0 |
Hyperprolactinemia/complications/*drug therapy | 7 | 100.0 |
Oligospermia/blood/*physiopathology | 2 | 100.0 |
*Sperm Count | 2 | 18.0 |
Apomorphine/diagnostic use | 2 | 66.0 |
Brain/drug effects/physiopathology | 2 | 33.0 |
Glucose/pharmacology | 2 | 1.0 |
Breast Neoplasms/*blood | 4 | 9.0 |
Body Height/*drug effects | 2 | 12.0 |
Pituitary Neoplasms/*drug therapy/radiography/secretion | 5 | 100.0 |
Triiodothyronine/therapeutic use | 3 | 50.0 |
*Pregnancy | 26 | 19.0 |
Autoantibodies/*analysis | 2 | 0.0 |
Pituitary Neoplasms/*complications/pathology/secretion | 4 | 80.0 |
Prolactinoma/*complications/pathology/secretion | 2 | 100.0 |
Bromocriptine/*administration & dosage/adverse effects/therapeutic use | 4 | 100.0 |
Dehydration/*physiopathology | 2 | 40.0 |
Haloperidol/*pharmacology | 2 | 33.0 |
Pituitary Gland, Anterior/drug effects/*secretion | 4 | 40.0 |
Sodium Chloride/pharmacology | 2 | 2.0 |
*Hypophysectomy | 3 | 25.0 |
Rats, Inbred Strains | 38 | 4.0 |
Microspheres | 3 | 1.0 |
Protirelin/administration & dosage/*diagnostic use | 3 | 100.0 |
Parkinson Disease/blood/*drug therapy | 3 | 75.0 |
Receptors, Dopamine/*drug effects/physiology | 3 | 100.0 |
Domperidone/diagnostic use | 11 | 100.0 |
Hypophysectomy/*methods | 2 | 100.0 |
*Pituitary Function Tests | 6 | 85.0 |
Pituitary Neoplasms/secretion/*surgery | 3 | 100.0 |
Adenoma/*diagnosis/secretion | 3 | 100.0 |
Pituitary Neoplasms/*diagnosis/secretion | 3 | 100.0 |
Adenoma/blood | 16 | 84.0 |
Cyproheptadine/diagnostic use | 2 | 100.0 |
Hypothyroidism/*blood | 10 | 38.0 |
Follicle Stimulating Hormone/*secretion | 9 | 100.0 |
Luteinizing Hormone/*secretion | 18 | 69.0 |
Pituitary Gland/drug effects/*secretion | 3 | 25.0 |
Clomiphene/therapeutic use | 3 | 30.0 |
Infertility, Female/drug therapy/*etiology | 2 | 100.0 |
Luteal Phase/*physiology | 3 | 25.0 |
Indomethacin/pharmacology | 2 | 0.0 |
Hydrocortisone/secretion | 7 | 29.0 |
Protirelin/administration & dosage/*pharmacology/therapeutic use | 2 | 100.0 |
Thyroxine/*blood | 4 | 11.0 |
Agar | 2 | 6.0 |
Antibodies | 2 | 0.0 |
Breast Neoplasms/*pathology | 3 | 1.0 |
Hormones/*pharmacology | 4 | 8.0 |
Pregnancy/*blood | 10 | 6.0 |
Acromegaly/blood/pathology | 2 | 100.0 |
Growth Hormone/blood/genetics | 2 | 100.0 |
Prolactin/blood/genetics | 3 | 100.0 |
DNA, Neoplasm/genetics | 2 | 0.0 |
Obesity/blood/*physiopathology | 2 | 12.0 |
Prolactin/analysis/*secretion | 2 | 66.0 |
Prolactinoma/*metabolism | 2 | 50.0 |
Receptors, Serotonin/drug effects/*physiology | 2 | 50.0 |
Amniotic Fluid/*metabolism | 4 | 10.0 |
Amenorrhea/physiopathology | 3 | 60.0 |
Pituitary Neoplasms/*physiopathology | 4 | 66.0 |
*Periodicity | 7 | 24.0 |
Stress, Psychological/blood/*physiopathology | 3 | 100.0 |
Ovum/physiology | 5 | 41.0 |
Temperature | 5 | 0.0 |
*Luteal Phase | 14 | 66.0 |
Clonidine/*pharmacology | 3 | 13.0 |
Pituitary Neoplasms/complications/*drug therapy/pathology | 2 | 66.0 |
Prolactinoma/complications/*drug therapy/pathology | 2 | 100.0 |
Estradiol/administration & dosage/pharmacology | 2 | 40.0 |
Progesterone/administration & dosage/*pharmacology | 2 | 100.0 |
Neuroimmunomodulation/physiology | 2 | 12.0 |
Clomiphene/administration & dosage | 2 | 100.0 |
Ovulation/*drug effects | 8 | 53.0 |
Hypertension/*physiopathology | 2 | 3.0 |
Pituitary Gland/*secretion | 5 | 29.0 |
Pituitary Hormones/*secretion | 4 | 40.0 |
Pituitary Neoplasms/blood/*therapy | 2 | 100.0 |
Prolactinoma/blood/*therapy | 2 | 100.0 |
Radiotherapy Dosage | 2 | 1.0 |
Ovary/*secretion | 2 | 100.0 |
Thymic Factor, Circulating/*metabolism | 2 | 33.0 |
Drug Evaluation | 8 | 3.0 |
Galactorrhea/drug therapy | 8 | 100.0 |
Anesthesia | 2 | 6.0 |
Cesarean Section | 2 | 3.0 |
Fetal Blood/metabolism | 5 | 8.0 |
Fetus/*physiology | 3 | 7.0 |
Argipressin/blood | 3 | 2.0 |
Adenoma/*metabolism/physiopathology | 2 | 100.0 |
Pituitary Neoplasms/*metabolism/physiopathology | 2 | 100.0 |
Adenoma/*complications/pathology/secretion | 2 | 66.0 |
Receptors, Thyrotropin-Releasing Hormone | 4 | 66.0 |
Corpus Luteum/*physiopathology | 3 | 100.0 |
Corpus Luteum/*physiology | 2 | 20.0 |
Receptors, Dopamine/drug effects | 24 | 92.0 |
Vasoactive Intestinal Peptide/*secretion | 2 | 16.0 |
Prolactinoma/complications | 2 | 100.0 |
Carcinoid Tumor/metabolism | 2 | 25.0 |
Hormones/metabolism | 6 | 20.0 |
Vasoactive Intestinal Peptide/blood | 3 | 7.0 |
Amenorrhea/complications | 3 | 100.0 |
Galactorrhea/complications | 3 | 100.0 |
Catecholamines/blood | 3 | 6.0 |
Chlorpromazine/pharmacology | 4 | 15.0 |
Pituitary Gland, Anterior/*drug effects | 6 | 75.0 |
Pregnancy Complications/*blood | 4 | 11.0 |
Acromegaly/drug therapy/*physiopathology | 2 | 66.0 |
Hypothalamus/secretion | 2 | 40.0 |
Fourier Analysis | 2 | 3.0 |
Administration, Intranasal | 2 | 2.0 |
Naltrexone/*pharmacology | 2 | 100.0 |
Testosterone/blood/*secretion | 2 | 50.0 |
Prolactin/metabolism/*secretion | 2 | 100.0 |
Androgens/secretion | 2 | 100.0 |
Pituitary Gland/drug effects/*physiology | 3 | 37.0 |
Insulin/physiology | 2 | 6.0 |
Pituitary Gland, Anterior/*physiology | 5 | 71.0 |
Prolactin/*analysis/blood | 6 | 100.0 |
Protirelin/antagonists & inhibitors/*pharmacology | 3 | 60.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Catecholamines/*blood | 5 | 15.0 |
Stress, Psychological/*complications | 3 | 33.0 |
Piribedil/*pharmacology | 3 | 100.0 |
Endorphins/physiology | 6 | 50.0 |
Naloxone/administration & dosage/*pharmacology | 6 | 100.0 |
Ovulation/physiology | 2 | 12.0 |
Clomiphene/*pharmacology | 3 | 42.0 |
Fertilization in Vitro/*drug effects | 3 | 42.0 |
Infertility, Female/therapy | 2 | 28.0 |
Oocytes/cytology | 2 | 14.0 |
Labor, Obstetric/*blood | 3 | 25.0 |
Arginine/*diagnostic use | 4 | 50.0 |
Somatotropin-Releasing Hormone/*diagnostic use | 6 | 18.0 |
Psychotic Disorders/blood/*diagnosis/psychology | 2 | 100.0 |
Receptors, Dopamine D2 | 3 | 20.0 |
Schizophrenia/blood/*diagnosis | 2 | 100.0 |
Hypogonadism/blood/*etiology | 2 | 50.0 |
Infertility, Male/*blood/etiology | 2 | 100.0 |
Dexamethasone/*diagnostic use | 5 | 38.0 |
Medroxyprogesterone 17-Acetate | 5 | 17.0 |
Progestins/*pharmacology | 3 | 13.0 |
Relaxin/*pharmacology | 2 | 100.0 |
Creatinine/blood | 2 | 0.0 |
Kidney Transplantation/*physiology | 2 | 4.0 |
Hypothalamus/*physiology | 5 | 17.0 |
Pituitary Neoplasms/blood/*drug therapy/radiography | 4 | 100.0 |
Prolactinoma/blood/*drug therapy/radiography | 2 | 100.0 |
Ovarian Follicle/*physiology | 2 | 8.0 |
Follicular Phase/*drug effects | 2 | 100.0 |
Postpartum Period/*drug effects | 3 | 100.0 |
Androstenedione/metabolism | 4 | 13.0 |
Ovary/drug effects/*enzymology | 2 | 50.0 |
Brain/*drug effects | 3 | 18.0 |
Receptors, Dopamine/*drug effects | 21 | 77.0 |
Milk, Human/secretion | 2 | 100.0 |
Pituitary Neoplasms/drug therapy/*secretion/surgery | 2 | 100.0 |
Androgens/*blood | 11 | 8.0 |
Dopamine Agents/therapeutic use | 2 | 22.0 |
Densitometry | 3 | 2.0 |
Pituitary Neoplasms/complications/secretion | 2 | 66.0 |
*Disease Models, Animal | 2 | 0.0 |
Angiotensin II/pharmacology | 2 | 2.0 |
Orchiectomy | 6 | 5.0 |
Menopause/physiology | 2 | 13.0 |
Ovarian Follicle/drug effects | 2 | 50.0 |
Circadian Rhythm/*drug effects | 5 | 41.0 |
Mesocricetus | 4 | 2.0 |
Gonadorelin/*analogs & derivatives/pharmacology | 4 | 100.0 |
Adenoma/surgery | 4 | 50.0 |
*Adrenalectomy | 2 | 18.0 |
Decidua/*drug effects/metabolism | 2 | 50.0 |
Islets of Langerhans/physiopathology | 2 | 20.0 |
Patch-Clamp Techniques | 2 | 0.0 |
Fetus/metabolism | 2 | 1.0 |
Oocytes/*cytology | 3 | 27.0 |
Chlorides/metabolism | 2 | 2.0 |
*Body Weight | 2 | 3.0 |
Hyperprolactinemia/drug therapy/etiology/*physiopathology | 2 | 100.0 |
Vehicles | 2 | 18.0 |
Pituitary Gland, Anterior/metabolism | 3 | 21.0 |
Placenta/*analysis | 2 | 7.0 |
Prolactin/*analysis/metabolism | 2 | 100.0 |
Testis/analysis | 2 | 25.0 |
Schizophrenia/*blood/diagnosis | 2 | 100.0 |
Renal Dialysis | 7 | 2.0 |
Cystic Fibrosis/*metabolism | 2 | 4.0 |
Skin Transplantation | 2 | 7.0 |
Apomorphine/*pharmacology | 4 | 50.0 |
Piperidines/*pharmacology | 7 | 12.0 |
Ritanserin | 2 | 66.0 |
Serotonin Antagonists/*pharmacology | 4 | 40.0 |
Adenoma/secretion | 7 | 87.0 |
Circadian Rhythm/drug effects | 8 | 57.0 |
Hypertension/blood | 2 | 11.0 |
Acromegaly/blood/*radiotherapy | 2 | 100.0 |
Fetal Blood/analysis | 7 | 13.0 |
Hematocrit | 3 | 0.0 |
Sodium/blood | 6 | 5.0 |
Maternal-Fetal Exchange | 6 | 4.0 |
Ovulation/drug effects | 16 | 55.0 |
Pituitary Gland/drug effects/physiology | 4 | 66.0 |
Estrogens/*blood | 2 | 4.0 |
Insulin/therapeutic use | 2 | 1.0 |
Kidney Failure, Chronic/*blood | 3 | 4.0 |
Somatotropin-Releasing Hormone/administration & dosage/*pharmacology | 3 | 17.0 |
Pituitary Neoplasms/complications/*secretion | 3 | 75.0 |
Pituitary Hormone-Releasing Hormones/*pharmacology | 7 | 53.0 |
Infertility, Female/*etiology | 2 | 66.0 |
Ovarian Function Tests | 3 | 50.0 |
*Thyroid Function Tests | 2 | 15.0 |
Levonorgestrel | 3 | 9.0 |
1-Methyl-3-isobutylxanthine/pharmacology | 3 | 3.0 |
B-Lymphocytes/*metabolism | 2 | 1.0 |
Cyclic AMP/physiology | 2 | 1.0 |
Prolactin/immunology | 2 | 66.0 |
Sleep/physiology | 7 | 30.0 |
Cyclic AMP/blood | 3 | 8.0 |
Ovary/*physiopathology | 4 | 57.0 |
Amenorrhea/blood | 16 | 76.0 |
Growth | 2 | 4.0 |
Puberty/*blood | 2 | 11.0 |
Spleen/cytology | 2 | 1.0 |
Anovulation/blood/*drug therapy | 5 | 83.0 |
Progesterone/*blood | 10 | 25.0 |
Guinea Pigs | 4 | 0.0 |
Receptors, Pituitary Hormone/*metabolism | 2 | 40.0 |
Triptorelin | 4 | 28.0 |
Adenoma/analysis | 2 | 33.0 |
Dopamine/*analysis | 2 | 25.0 |
Growth Hormone/analysis/secretion | 2 | 100.0 |
Pituitary Gland/*analysis | 3 | 27.0 |
Pituitary Neoplasms/*analysis/pathology | 2 | 100.0 |
Plasma/analysis | 2 | 28.0 |
Headache/etiology | 2 | 20.0 |
Prolactin/biosynthesis/*metabolism | 2 | 66.0 |
Clomiphene/pharmacology | 5 | 71.0 |
Prolactin/*antagonists & inhibitors | 2 | 66.0 |
Animals, Newborn | 3 | 0.0 |
Dietary Proteins/*pharmacology | 2 | 15.0 |
Receptors, Dopamine/drug effects/*metabolism | 2 | 100.0 |
Goserelin | 2 | 20.0 |
Prostatic Neoplasms/blood/*drug therapy | 3 | 20.0 |
Estradiol/*metabolism | 2 | 3.0 |
Oocytes/*drug effects | 2 | 40.0 |
Fetal Blood/*analysis | 8 | 22.0 |
Hyperprolactinemia/*blood/genetics | 2 | 100.0 |
Psychological Tests | 3 | 7.0 |
Anorexia Nervosa/*blood/complications | 2 | 100.0 |
Pituitary Hormone-Releasing Hormones/blood | 2 | 100.0 |
*Follicular Phase | 7 | 58.0 |
*Labor, Obstetric | 5 | 21.0 |
Testis/*analysis | 2 | 50.0 |
Receptors, Opioid/drug effects | 3 | 60.0 |
Estrenes/*pharmacology | 2 | 22.0 |
Medroxyprogesterone/*analogs & derivatives/pharmacology | 2 | 28.0 |
Medroxyprogesterone/administration & dosage/analogs & derivatives | 2 | 50.0 |
Rest | 2 | 4.0 |
Pituitary Neoplasms/diagnosis/*secretion | 4 | 100.0 |
Sleep Stages/drug effects | 2 | 14.0 |
Semen/*metabolism | 3 | 16.0 |
Luteal Phase/drug effects | 4 | 50.0 |
Hypothyroidism/physiopathology | 3 | 100.0 |
Peptide Mapping | 2 | 0.0 |
Pituitary Gland/radiography | 2 | 50.0 |
Pituitary Neoplasms/physiopathology | 3 | 60.0 |
Sella Turcica/radiography | 7 | 100.0 |
United States | 2 | 0.0 |
Administration, Intravaginal | 2 | 10.0 |
Gonadal Steroid Hormones/*metabolism | 3 | 20.0 |
Ovarian Follicle/*metabolism | 2 | 7.0 |
Testosterone/metabolism | 2 | 1.0 |
Amenorrhea/blood/*physiopathology | 3 | 75.0 |
Gonadorelin/blood | 2 | 33.0 |
Chemotherapy, Adjuvant | 2 | 0.0 |
Hyperprolactinemia/blood/*complications | 3 | 100.0 |
Depression, Chemical | 18 | 9.0 |
Perfusion | 5 | 2.0 |
Hypothyroidism/blood/*physiopathology | 2 | 28.0 |
Pituitary Neoplasms/*physiopathology/secretion | 3 | 60.0 |
*Ovulation | 6 | 31.0 |
Estradiol/*secretion | 3 | 37.0 |
Progesterone/*secretion | 3 | 33.0 |
Radioimmunoassay/*methods | 2 | 2.0 |
Heart Rate | 5 | 2.0 |
*Exertion | 14 | 8.0 |
Stress | 2 | 3.0 |
Bulimia/*blood | 3 | 33.0 |
Corpus Luteum/*drug effects | 2 | 50.0 |
Hyperprolactinemia/chemically induced/*physiopathology | 4 | 100.0 |
Metoclopramide | 2 | 100.0 |
Prostate/metabolism | 2 | 2.0 |
Hypoglycemia/chemically induced/*physiopathology | 2 | 25.0 |
Polycystic Ovary Syndrome/*physiopathology | 2 | 28.0 |
Protirelin/administration & dosage/*pharmacology | 3 | 42.0 |
Infertility, Female/blood/*therapy | 2 | 66.0 |
Acromegaly/*blood/surgery | 2 | 40.0 |
Insulin-Like Growth Factor I/blood | 3 | 17.0 |
Protirelin/physiology | 2 | 25.0 |
Cimetidine/*pharmacology | 6 | 40.0 |
Umbilical Arteries | 2 | 11.0 |
Organ Size | 10 | 5.0 |
Penile Erection | 2 | 40.0 |
Calcitonin/*pharmacology | 2 | 11.0 |
Acromegaly/*blood/drug therapy | 4 | 40.0 |
Chick Embryo | 2 | 0.0 |
Acromegaly/*physiopathology | 6 | 66.0 |
Amniotic Fluid/*analysis | 8 | 11.0 |
Methods | 3 | 1.0 |
Pituitary Gland/analysis | 2 | 33.0 |
Chorionic Gonadotropin/*administration & dosage | 3 | 37.0 |
Menotropins/*administration & dosage | 5 | 83.0 |
Gonadorelin/administration & dosage/*pharmacology | 2 | 50.0 |
Lactation Disorders/*etiology | 3 | 100.0 |
Sodium Chloride/*pharmacology | 2 | 6.0 |
Amenorrhea/*blood/etiology | 3 | 60.0 |
Statistics | 2 | 0.0 |
Testis/*physiology | 5 | 12.0 |
Receptors, Estrogen/*analysis | 2 | 0.0 |
Ovulation Induction/methods | 3 | 37.0 |
Dexamethasone/diagnostic use | 5 | 13.0 |
Depressive Disorder/blood/*diagnosis/drug therapy | 2 | 100.0 |
Prolactin/biosynthesis/*secretion | 2 | 66.0 |
Prolactin-Releasing Hormone/*physiology | 2 | 100.0 |
Hydrocortisone/*pharmacology | 3 | 7.0 |
Endoplasmic Reticulum/ultrastructure | 2 | 15.0 |
Golgi Apparatus/ultrastructure | 2 | 18.0 |
Cyproterone Acetate | 6 | 42.0 |
Depressive Disorder/*blood | 2 | 25.0 |
Testis/drug effects/*physiology | 3 | 75.0 |
Serotonin/metabolism/*physiology | 2 | 66.0 |
Adenoma/complications/*secretion | 2 | 66.0 |
Postpartum Period/*metabolism | 3 | 42.0 |
Breast Neoplasms/*blood/drug therapy | 2 | 20.0 |
Trophoblasts/*metabolism | 2 | 4.0 |
Liver/drug effects/*metabolism | 3 | 4.0 |
Magnesium/pharmacology | 4 | 3.0 |
Magnesium Chloride | 4 | 28.0 |
*Postpartum Period | 18 | 52.0 |
Cyclosporins/*pharmacology | 2 | 5.0 |
Hyperprolactinemia/*complications/pathology | 2 | 100.0 |
*Fixation, Ocular | 2 | 66.0 |
Scotoma/*physiopathology | 2 | 100.0 |
Lipotropin/blood | 2 | 66.0 |
Nomifensine/pharmacology | 4 | 100.0 |
*Body Height | 2 | 4.0 |
Cell Count | 2 | 0.0 |
Lactation Disorders/*physiopathology | 6 | 100.0 |
Semen/*analysis | 2 | 14.0 |
Transplantation, Heterologous | 2 | 0.0 |
*Body Temperature | 4 | 15.0 |
Bipolar Disorder/blood | 2 | 66.0 |
Somatomedins/*blood | 5 | 31.0 |
Amenorrhea/*blood/complications | 3 | 75.0 |
Hyperprolactinemia/*blood/complications | 3 | 100.0 |
*Physical Education and Training | 2 | 3.0 |
Sleep/drug effects | 3 | 25.0 |
Octreotide | 2 | 16.0 |
Somatostatin/*analogs & derivatives/therapeutic use | 2 | 18.0 |
Synaptic Transmission | 3 | 7.0 |
Hydroxyindoleacetic Acid/urine | 2 | 18.0 |
Methoxyhydroxyphenylglycol/urine | 2 | 66.0 |
Lactates/blood | 2 | 2.0 |
Lactic Acid | 2 | 3.0 |
*Running | 3 | 10.0 |
Mammary Glands, Animal/*metabolism | 2 | 10.0 |
Cyproterone/*analogs & derivatives/therapeutic use | 3 | 75.0 |
Dehydroepiandrosterone/blood | 8 | 11.0 |
Ethinyl Estradiol/*therapeutic use | 2 | 22.0 |
Somatostatin/*pharmacology | 4 | 8.0 |
Milk, Human/*secretion | 2 | 100.0 |
Homovanillic Acid/urine | 2 | 20.0 |
Empty Sella Syndrome/blood | 2 | 100.0 |
Pituitary Diseases/*blood | 3 | 75.0 |
Pituitary Gland, Anterior/drug effects | 5 | 62.0 |
Menstruation Disturbances/drug therapy | 3 | 100.0 |
Amenorrhea/blood/drug therapy | 5 | 100.0 |
Infertility, Female/blood/*drug therapy | 3 | 60.0 |
Mammary Glands, Animal/*analysis | 2 | 66.0 |
*Radioligand Assay | 2 | 33.0 |
Amenorrhea/*drug therapy/physiopathology | 2 | 100.0 |
Sulpiride | 2 | 66.0 |
Pituitary Neoplasms/drug therapy/*secretion | 4 | 80.0 |
Laparoscopy | 2 | 5.0 |
Clonidine/pharmacology | 3 | 20.0 |
Receptors, Opioid/*drug effects | 2 | 40.0 |
Alcoholism/*blood | 2 | 12.0 |
Ergolines/administration & dosage/*pharmacology | 2 | 100.0 |
Adenoma/blood/*secretion | 2 | 100.0 |
Decidua/*analysis | 2 | 50.0 |
Melatonin/blood/*pharmacology | 2 | 100.0 |
Epilepsy/*blood | 3 | 100.0 |
Cimetidine/pharmacology | 4 | 18.0 |
Neurotransmitters/*physiology | 2 | 6.0 |
Cholesterol/blood | 4 | 0.0 |
Triglycerides/blood | 3 | 0.0 |
Lactation Disorders/*complications | 5 | 100.0 |
Fibrocystic Breast Disease/*blood | 3 | 75.0 |
Acromegaly/blood | 3 | 30.0 |
Pituitary Neoplasms/blood/secretion | 2 | 66.0 |
Glycoprotein Hormones, alpha Subunit | 2 | 40.0 |
Testosterone/analogs & derivatives/pharmacology | 2 | 100.0 |
Anovulation/drug therapy | 2 | 100.0 |
Pituitary Hormone-Releasing Hormones/*administration & dosage | 2 | 100.0 |
beta-Endorphin | 7 | 31.0 |
Pituitary Neoplasms/*blood/secretion | 2 | 100.0 |
Sulpiride/administration & dosage/*pharmacology | 3 | 100.0 |
Transsexualism/*blood | 2 | 100.0 |
Polycystic Ovary Syndrome/*drug therapy | 4 | 40.0 |
Prolactin/analysis/*blood | 2 | 100.0 |
Vascular Headaches/*blood | 2 | 100.0 |
Metoclopramide/*adverse effects | 2 | 100.0 |
Pituitary Neoplasms/secretion | 9 | 81.0 |
Schizophrenia/drug therapy/physiopathology | 2 | 66.0 |
Microsomes, Liver/*metabolism | 2 | 1.0 |
Receptors, Prolactin/immunology/*metabolism | 2 | 100.0 |
Metergoline/*therapeutic use | 6 | 100.0 |
Sucking Behavior/physiology | 2 | 100.0 |
Buserelin/pharmacology | 2 | 20.0 |
Lactation Disorders/*blood | 11 | 100.0 |
Adenoma/*drug therapy | 4 | 80.0 |
Dopamine beta-Hydroxylase/*blood | 2 | 1.0 |
Chorionic Gonadotropin/*blood | 4 | 4.0 |
Estriol/blood | 6 | 18.0 |
Buspirone | 3 | 100.0 |
Anovulation/blood | 3 | 75.0 |
Pregnancy Complications/blood | 2 | 22.0 |
Lung/*metabolism | 2 | 2.0 |
Amniotic Fluid/metabolism | 2 | 6.0 |
Prolactin/*metabolism/secretion | 2 | 66.0 |
*Aging | 5 | 3.0 |
Metergoline/*pharmacology | 5 | 83.0 |
Galactorrhea/*diagnosis | 2 | 100.0 |
Hyperprolactinemia/diagnosis | 2 | 100.0 |
Lactation Disorders/*diagnosis | 2 | 100.0 |
Pituitary Hormone-Releasing Hormones/*diagnostic use | 7 | 87.0 |
*Superovulation | 2 | 100.0 |
Levodopa/therapeutic use | 4 | 14.0 |
Schizophrenia/blood/drug therapy | 2 | 50.0 |
Autoantibodies/analysis | 2 | 1.0 |
Pituitary Gland/immunology | 2 | 100.0 |
Gynecomastia/blood | 3 | 100.0 |
Impotence/blood | 2 | 100.0 |
Hypogonadism/*blood | 4 | 57.0 |
Pentagastrin/*pharmacology | 2 | 66.0 |
Corticotropin-Releasing Hormone/*diagnostic use | 3 | 23.0 |
Hypothyroidism/blood | 2 | 15.0 |
Biological Availability | 2 | 0.0 |
Sleep Stages/*physiology | 3 | 15.0 |
Pituitary Gland, Anterior/physiology | 2 | 66.0 |
Thyrotropin/*blood/secretion | 4 | 57.0 |
Ovary/pathology | 2 | 6.0 |
Steroids/*blood | 2 | 13.0 |
*Food | 4 | 4.0 |
Lisuride/adverse effects/analogs & derivatives/*therapeutic use | 3 | 100.0 |
Pregnancy in Diabetics/*metabolism | 2 | 22.0 |
Anestrus | 2 | 100.0 |
Pimozide/pharmacology | 4 | 57.0 |
Adenoma/*surgery | 2 | 33.0 |
Pituitary Neoplasms/*surgery | 2 | 50.0 |
Testis/*physiopathology | 9 | 39.0 |
Hypogonadism/*blood/drug therapy/etiology | 2 | 100.0 |
Infusions, Parenteral | 16 | 11.0 |
Fetus/*metabolism | 4 | 5.0 |
Bromocriptine/diagnostic use/*pharmacology | 2 | 100.0 |
Adenoma/secretion/surgery | 2 | 50.0 |
Chlorpromazine/diagnostic use | 5 | 100.0 |
Amenorrhea/blood/etiology | 3 | 100.0 |
Pituitary Neoplasms/*blood/surgery | 3 | 60.0 |
Sphenoid Bone | 2 | 100.0 |
Hypertension/*metabolism | 2 | 6.0 |
Natriuresis | 2 | 13.0 |
Potassium/urine | 2 | 5.0 |
Anovulation/*blood | 2 | 40.0 |
Estradiol/blood/*pharmacology | 2 | 40.0 |
Follicle Stimulating Hormone/blood/*secretion | 6 | 85.0 |
*Tomography, X-Ray Computed | 4 | 4.0 |
Oxytocin/blood/*secretion | 2 | 22.0 |
Pituitary Gland, Anterior/*drug effects/secretion | 3 | 50.0 |
Heat | 2 | 0.0 |
Thyroxine/blood/therapeutic use | 3 | 20.0 |
Pyrilamine/pharmacology | 2 | 50.0 |
Bromocriptine/*diagnostic use | 9 | 100.0 |
*Puberty | 3 | 12.0 |
Oligomenorrhea/blood | 2 | 50.0 |
Running | 3 | 8.0 |
Receptors, Cell Surface/*metabolism | 8 | 1.0 |
Receptors, Prolactin | 17 | 85.0 |
Receptors, Somatotropin | 2 | 28.0 |
Amnion/metabolism | 3 | 18.0 |
Chorion/metabolism | 2 | 12.0 |
Fetal Membranes/*metabolism | 2 | 25.0 |
Glucuronidase/metabolism | 2 | 6.0 |
Placenta/metabolism | 2 | 1.0 |
Corticotropin/diagnostic use | 2 | 9.0 |
Median Eminence/physiology | 2 | 50.0 |
Amenorrhea/*drug therapy/etiology | 3 | 100.0 |
Catecholamines/biosynthesis | 3 | 23.0 |
Dopamine/*administration & dosage | 2 | 33.0 |
Methyltyrosines/pharmacology | 6 | 75.0 |
alpha-Methyltyrosine | 7 | 63.0 |
Uremia/*blood/therapy | 2 | 11.0 |
Peptides/*blood | 2 | 2.0 |
Gastrointestinal Diseases/drug therapy | 2 | 100.0 |
Dopamine/administration & dosage/*diagnostic use | 2 | 100.0 |
Bipolar Disorder/*blood/drug therapy | 2 | 33.0 |
Rats, Inbred SHR | 2 | 2.0 |
Blood Glucose/*metabolism | 3 | 1.0 |
Glucagon/blood | 2 | 2.0 |
Estriol/*blood | 3 | 8.0 |
D-Ala(2),MePhe(4),Met(0)-ol-enkephalin | 2 | 66.0 |
Methysergide/pharmacology | 4 | 57.0 |
Hypogonadism/blood/*diagnosis | 2 | 100.0 |
Cimetidine/adverse effects/*pharmacology | 2 | 100.0 |
Neural Pathways/drug effects | 2 | 66.0 |
Synaptic Transmission/drug effects | 2 | 7.0 |
Diabetes Mellitus, Type 1/*metabolism | 2 | 3.0 |
Dopamine/*diagnostic use | 6 | 85.0 |
Hyperprolactinemia/metabolism | 2 | 100.0 |
Gonads/drug effects | 2 | 100.0 |
Receptors, Cell Surface/metabolism | 5 | 1.0 |
Lactation Disorders/*drug therapy | 14 | 100.0 |
Semen/analysis | 2 | 22.0 |
Liver/*enzymology | 2 | 0.0 |
Microsomes, Liver/enzymology | 3 | 1.0 |
Adrenal Glands/*secretion | 2 | 50.0 |
Histamine/*pharmacology | 3 | 8.0 |
Carbidopa/*therapeutic use | 2 | 28.0 |
Levodopa/*therapeutic use | 2 | 11.0 |
Receptors, Cell Surface/drug effects | 3 | 16.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Diabetes Mellitus, Type 1/*blood/complications | 2 | 15.0 |
Pituitary Neoplasms/*radiotherapy/secretion | 2 | 100.0 |
Phospholipids/*pharmacology | 2 | 13.0 |
Craniopharyngioma/*secretion | 2 | 100.0 |
Abdomen | 2 | 2.0 |
Benserazide/*pharmacology | 2 | 100.0 |
Hydrazines/*pharmacology | 2 | 50.0 |
Serotonin/pharmacology | 3 | 10.0 |
Galactorrhea/physiopathology | 4 | 100.0 |
Protein-Tyrosine Kinase/genetics/metabolism | 2 | 2.0 |
Lisuride/*pharmacology | 2 | 100.0 |
Amenorrhea/etiology/*physiopathology | 3 | 100.0 |
Aromatase/*metabolism | 2 | 33.0 |
Oxidoreductases/*metabolism | 3 | 7.0 |
Chemistry | 2 | 0.0 |
Physical Endurance | 2 | 6.0 |
Labor, Obstetric | 4 | 9.0 |
Luteinizing Hormone/pharmacology | 3 | 9.0 |
Natriuresis/drug effects | 2 | 7.0 |
Animals, Newborn/*metabolism | 2 | 15.0 |
Receptors, LH | 4 | 66.0 |
Binding Sites/drug effects | 2 | 3.0 |
Receptors, Cell Surface/*drug effects | 4 | 33.0 |
Hydroxyindoleacetic Acid/blood | 2 | 66.0 |
Pituitary Irradiation | 3 | 100.0 |
Pituitary Neoplasms/*secretion/surgery | 3 | 100.0 |
Nomifensine/*pharmacology | 3 | 75.0 |
*Dopamine Antagonists | 6 | 85.0 |
Pergolide | 3 | 100.0 |
Sympathetic Nervous System/*physiology | 3 | 6.0 |
Isoquinolines/*pharmacology | 3 | 11.0 |
Chlorpheniramine/pharmacology | 2 | 40.0 |
Promethazine/pharmacology | 2 | 66.0 |
Receptors, Histamine/*physiology | 2 | 50.0 |
Adenoma/blood/*drug therapy/radiography | 2 | 100.0 |
Pituitary Diseases/*blood/complications | 2 | 100.0 |
Spermatozoa/*physiology | 3 | 7.0 |
Lypressin/pharmacology | 3 | 37.0 |
Electroshock | 2 | 15.0 |
Adenoma/blood/drug therapy | 3 | 100.0 |
Estrogens/urine | 2 | 28.0 |
Pituitary Neoplasms/secretion/surgery | 2 | 66.0 |
Castration | 7 | 15.0 |
Immune Sera/immunology | 2 | 1.0 |
Cimetidine/diagnostic use | 3 | 50.0 |
Pituitary Neoplasms/physiopathology/*secretion | 3 | 100.0 |
Pimozide/*therapeutic use | 3 | 100.0 |
Insulin-Like Growth Factor I | 3 | 33.0 |
Prolactin/*biosynthesis/immunology | 2 | 100.0 |
Receptors, Cell Surface/drug effects/*metabolism | 2 | 4.0 |
Sella Turcica/*radiography | 2 | 66.0 |
Phosphates/blood | 2 | 3.0 |
Aging | 4 | 1.0 |
Parkinson Disease/drug therapy/*metabolism | 2 | 66.0 |
Hypothalamo-Hypophyseal System/drug effects/*secretion | 2 | 66.0 |
Amenorrhea/blood/*drug therapy | 3 | 100.0 |
Adenoma/metabolism | 2 | 5.0 |
Pituitary Hormones, Anterior/*metabolism | 2 | 66.0 |
Ergolines/adverse effects/metabolism/*pharmacology | 2 | 100.0 |
Chlorpromazine/*diagnostic use | 4 | 80.0 |
Aldosterone/*blood | 5 | 10.0 |
Hypopituitarism/*blood | 2 | 66.0 |
Testis/physiology | 3 | 8.0 |
Insulin/*diagnostic use | 7 | 36.0 |
Insulin | 2 | 13.0 |
Phentolamine/pharmacology | 2 | 9.0 |
Membranes/metabolism | 2 | 4.0 |
Goiter/complications | 2 | 100.0 |
Milk, Human/*analysis | 3 | 13.0 |
*Menstruation | 11 | 27.0 |
Infertility, Female/drug therapy | 3 | 75.0 |
Spermatozoa/physiology | 2 | 7.0 |
Receptors, Estrogen/*drug effects | 2 | 14.0 |
*Sexual Maturation | 2 | 33.0 |
Reaction Time/drug effects | 2 | 11.0 |
*Infant, Premature | 2 | 3.0 |
Pregnenolone/blood | 2 | 50.0 |
Amino Acid Motifs | 2 | 0.0 |
Contraceptives, Oral/*pharmacology | 2 | 9.0 |
Ethinyl Estradiol/*pharmacology | 2 | 11.0 |
Sulpiride/*diagnostic use | 5 | 100.0 |
Amenorrhea/drug therapy | 4 | 80.0 |
Pituitary Neoplasms/blood/drug therapy | 2 | 100.0 |
*Sella Turcica | 2 | 100.0 |
Breast/*growth & development | 3 | 27.0 |
Adenoma/*physiopathology/secretion | 2 | 50.0 |
Metergoline/pharmacology | 4 | 66.0 |
Infertility, Male/pathology/*physiopathology | 2 | 100.0 |
Oligospermia/physiopathology | 2 | 50.0 |
Spermatozoa/abnormalities/*physiology | 2 | 100.0 |
Anorexia Nervosa/*physiopathology | 5 | 50.0 |
Estradiol/physiology | 2 | 22.0 |
Follicle Stimulating Hormone/physiology | 3 | 25.0 |
Luteinizing Hormone/physiology | 3 | 42.0 |
Klinefelter Syndrome/blood | 2 | 66.0 |
Testicular Diseases/blood | 2 | 100.0 |
Schizophrenia/blood/*physiopathology | 2 | 66.0 |
Butorphanol/*pharmacology | 2 | 100.0 |
Morphinans/*pharmacology | 3 | 100.0 |
Craniopharyngioma/*blood/surgery | 2 | 100.0 |
Postoperative Complications/blood | 3 | 17.0 |
Catecholamines/biosynthesis/*physiology | 2 | 100.0 |
Epinephrine/pharmacology | 2 | 2.0 |
Puberty, Precocious/*blood | 3 | 30.0 |
Alprostadil | 2 | 15.0 |
Benzamides/pharmacology | 2 | 9.0 |
Prostaglandins E/*pharmacology | 2 | 14.0 |
Theophylline/*pharmacology | 2 | 22.0 |
Turkeys | 2 | 12.0 |
Valproic Acid/pharmacology | 2 | 18.0 |
Adrenal Insufficiency/blood/complications/*congenital | 2 | 100.0 |
Hypogonadism/blood/*physiopathology | 2 | 100.0 |
Dopamine/*physiology/urine | 2 | 100.0 |
Epinephrine/urine | 2 | 28.0 |
Norepinephrine/urine | 2 | 15.0 |
*Renin-Angiotensin System | 2 | 7.0 |
Receptors, Dopamine/analysis/*drug effects | 2 | 100.0 |
Cerebrospinal Fluid Proteins/analysis | 2 | 8.0 |
Chlorpromazine/*pharmacology | 3 | 14.0 |
Receptors, Cell Surface/*analysis | 2 | 1.0 |
Nomifensine/diagnostic use | 2 | 100.0 |
Potassium/blood | 3 | 3.0 |
Parathyroid Hormone/blood | 4 | 2.0 |
Isoquinolines/*diagnostic use | 4 | 100.0 |
Nomifensine/*diagnostic use | 4 | 100.0 |
Anti-Anxiety Agents/*pharmacology | 2 | 14.0 |
Pyrimidines/*pharmacology | 2 | 3.0 |
Pituitary Neoplasms/diagnosis | 2 | 50.0 |
Pimozide/*pharmacology | 3 | 75.0 |
Galactorrhea/*drug therapy/etiology | 2 | 100.0 |
Testosterone/blood/*pharmacology | 2 | 100.0 |
Seminiferous Tubules/*physiopathology | 2 | 100.0 |
Glucose/diagnostic use | 2 | 14.0 |
Insulin/*blood | 3 | 1.0 |
Dehydroepiandrosterone/*blood | 3 | 16.0 |
Sulpiride/administration & dosage | 2 | 100.0 |
Pneumoencephalography | 2 | 100.0 |
Hypoparathyroidism/*blood | 2 | 66.0 |
Pituitary Diseases/metabolism | 2 | 100.0 |
Pituitary Neoplasms/surgery | 2 | 100.0 |
Galactorrhea/blood/*drug therapy | 2 | 100.0 |
Protirelin/*administration & dosage/diagnostic use | 2 | 100.0 |
*Diabetes Complications | 2 | 3.0 |
Amenorrhea/*blood/drug therapy | 3 | 100.0 |
Estrone/*analogs & derivatives | 2 | 50.0 |
Apomorphine/*diagnostic use | 2 | 100.0 |
*Pregnancy Trimester, Third | 2 | 25.0 |
Ethinyl Estradiol/administration & dosage/pharmacology | 2 | 40.0 |
Smoking | 3 | 0.0 |
Lactation Disorders/*chemically induced | 2 | 66.0 |
Hypoglycemia/physiopathology | 2 | 66.0 |
Androstenedione/*blood | 3 | 16.0 |
Posture | 3 | 3.0 |
Renin/*blood | 3 | 3.0 |
Thyroid Hormones/secretion | 2 | 100.0 |
Chlorpromazine/blood/*therapeutic use | 2 | 100.0 |
Steroids/biosynthesis | 2 | 5.0 |
Hyperparathyroidism/*blood | 2 | 33.0 |
Liver Cirrhosis, Alcoholic/*blood | 2 | 14.0 |
Testis/*drug effects | 3 | 27.0 |
Puerperal Disorders/*blood | 2 | 66.0 |
Benzamides/*pharmacology | 2 | 9.0 |
Adenoma/*drug therapy/secretion | 2 | 100.0 |
Acromegaly/cerebrospinal fluid | 2 | 100.0 |
Receptors, Histamine/*metabolism | 2 | 100.0 |
Receptors, Histamine H2/*metabolism | 2 | 40.0 |
Duodenal Ulcer/drug therapy | 2 | 100.0 |
Substance Withdrawal Syndrome/*metabolism | 2 | 66.0 |
Anovulation/*blood/drug therapy | 2 | 100.0 |
Cimetidine/*diagnostic use | 3 | 75.0 |
Guanidines/*diagnostic use | 4 | 100.0 |
Adenoma/*physiopathology | 2 | 22.0 |
Guanidines/*pharmacology | 4 | 23.0 |
Pyridoxine/*therapeutic use | 2 | 20.0 |
Oligomenorrhea/etiology | 2 | 66.0 |
Climacteric | 2 | 25.0 |
Receptors, Cell Surface/analysis | 2 | 2.0 |
Hyperthyroidism/*metabolism | 2 | 28.0 |
Amenorrhea/*drug therapy | 6 | 100.0 |
Galactorrhea/*drug therapy | 4 | 100.0 |
Vasopressins/*secretion | 2 | 18.0 |
Endorphins/*pharmacology | 2 | 25.0 |
Lisuride/*therapeutic use | 2 | 100.0 |
*Infant, Newborn | 3 | 6.0 |
*Temperature | 2 | 6.0 |
Drug Combinations/therapeutic use | 2 | 28.0 |
Diabetes Mellitus/*blood | 2 | 2.0 |
Kidney Failure, Chronic/*metabolism | 2 | 9.0 |
Apomorphine/pharmacology | 2 | 9.0 |
Antidepressive Agents/*pharmacology | 2 | 7.0 |
Atrophy | 3 | 2.0 |
Vaginal Smears | 2 | 3.0 |
Galactorrhea/*complications | 2 | 100.0 |
Thyroidectomy | 2 | 1.0 |
Calcitonin/*blood | 2 | 3.0 |
Chlorpromazine/administration & dosage/*therapeutic use | 2 | 100.0 |
Haloperidol/diagnostic use | 3 | 100.0 |
Parathyroid Hormone/*diagnostic use | 2 | 66.0 |
Pseudohypoparathyroidism/*blood | 2 | 50.0 |
Benzimidazoles/*pharmacology | 3 | 13.0 |
Domperidone | 7 | 100.0 |
Chorionic Gonadotropin/diagnostic use | 2 | 25.0 |
Hypoglycemia/*blood/chemically induced | 2 | 25.0 |
Prolactin/*blood/pharmacology | 2 | 100.0 |
Endorphins/*diagnostic use | 2 | 100.0 |
Benzimidazoles/*diagnostic use | 3 | 75.0 |
Piperidines/*diagnostic use | 3 | 60.0 |
Cyproheptadine/*diagnostic use | 2 | 100.0 |
Cushing Syndrome/physiopathology | 2 | 66.0 |
Vaginal Creams, Foams and Jellies | 2 | 50.0 |
Pregnancy/*drug effects | 2 | 100.0 |
Lisuride/administration & dosage/*therapeutic use | 3 | 100.0 |
Parathyroid Hormone/blood/*diagnostic use | 2 | 100.0 |
Haplorhini | 4 | 1.0 |
Depression/*blood | 2 | 33.0 |
Infertility, Female/drug therapy/etiology | 2 | 100.0 |
Amenorrhea/therapy | 2 | 100.0 |
*Hypothalamus | 2 | 50.0 |
Adrenal Glands/drug effects | 2 | 33.0 |
Huntington Disease/*blood | 4 | 80.0 |
Hypothyroidism/*metabolism | 2 | 20.0 |
Lisuride/administration & dosage/*pharmacology | 2 | 100.0 |
Estrogens, Conjugated (USP)/*diagnostic use | 2 | 100.0 |
Delivery, Obstetric | 2 | 5.0 |
Acromegaly/physiopathology | 2 | 66.0 |
Ergolines/*diagnostic use | 3 | 100.0 |
Levodopa/administration & dosage/*pharmacology | 3 | 60.0 |
Breast | 2 | 6.0 |
Thyroid Gland/physiology | 2 | 15.0 |
Triiodothyronine/metabolism | 2 | 5.0 |
Carbidopa/*diagnostic use | 2 | 100.0 |
Protirelin/*analogs & derivatives/diagnostic use | 2 | 100.0 |
Adenoma/blood/*cerebrospinal fluid | 2 | 100.0 |
Prostate/*metabolism | 2 | 2.0 |
Serotonin Antagonists | 3 | 100.0 |
Thyrotropin/pharmacology | 2 | 3.0 |
